VERSATILE DISPLAY SCAFFOLDS FOR PROTEINS

Abstract

Provided are processes and materials for solving biological or structural information about proteins or other organic molecules. The processes capitalize on a rigid multimeric nanocage formed from self-assembling substructure proteins. The processes and materials allow for recognition and tight, optionally covalent, bonding of any protein molecule with a tag complementary to a capture sequence on the nanocage. The processes and materials may be used to obtain biological or structural information by cryo-electron microscopy and overcome prior limitations of target protein size or salt concentration.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application depends from and claims priority to U.S. Provisional Application No. 62/472,119 filed Mar. 16, 2017, the entire contents of which are incorporated herein by reference.

FIELD

[0003] The disclosure relates to methods of cryo-electron microscopy and reagents useful for improved imaging of target molecules.

BACKGROUND

[0004] Revolutionary improvements have recently propelled Cryogenic Electron Microscopy (cryo-Electron Microscopy, Cryo-EM) to the front of the field of Structural Biology, with several structures now being reported at near atomic level resolution. However, there is a lower size limit of the molecules that can be imaged (.about.200 kilodaltons). As many macromolecules-of-interest are smaller than this, the use of Cryo-EM for structure determination has not be feasible for most people. Competing methods have genetically fused these proteins of interest to larger proteins to increase the overall protein size above the lower size limit. However, these scaffold proteins have not been sufficiently rigid or regular, required genetic fusions for each new protein-of-interest, and have only provided modest resolution of the structure of the protein-of-interest.

[0005] As such, new reagents and methods are needed for improved structural resolution of target molecules.

SUMMARY

[0006] The following summary is provided to facilitate an understanding of some of the innovative features unique to the present disclosure and is not intended to be a full description. A full appreciation of the various aspects of the disclosure can be gained by taking the entire specification, claims, drawings, and abstract as a whole.

[0007] Provided are multimeric, self-assembling structures such as nanocages and processes utilizing them for obtaining biological and/or structural information about one or more target proteins. The processes capitalize on the power of cryo-electron microscopy or other system capable of resolving the presence or absence of a protein-protein interaction where solution structures of one or more target proteins are enhanced by bonding to an engineered nanocage with sufficient rigidity to allow its use as a source for solution of information of the target protein bound thereto.

[0008] A process includes associating a target protein with a multimeric self-assembling protein structure to form a target complex, and subjecting the target complex to cryo-electron microscopy, transmission electron microscopy, or combinations thereof, whereby the multimeric self-assembling protein structure serves as a scaffold for obtaining biological or structural information related to the target protein such as but not limited to solution of a three-dimensional structure of the target protein. In some aspects, the protein has a molecular weight of 200 kilodaltons or less. In some aspects, a value of resolution of said three-dimensional structure is less than 20 angstroms. Optionally, the protein has a molecular weight of 200 kilodaltons or less and a value of resolution of said three-dimensional structure is less than 20 angstroms. The multimeric self-assembling protein structure, the target protein, or both are or include optionally non-naturally occurring proteins in that at least one amino acid or other modification on the primary structure is not found in nature.

[0009] The multimeric self-assembling protein structure may include a plurality of protein substructures, wherein one or more of the protein substructures comprises a capture sequence, the capture sequence expressed at the N-terminus of the protein substructure or within 10 amino acids from the N-terminus of the protein substructure. In alternative aspects, the capture sequence may be expressed at the C-terminus of the protein substructure or within 10 amino acids from the C-terminus of the protein substructure. Optionally, the capture sequence may be expressed at both the N-terminus and the C-terminus of the protein substructure or within 10 amino acids from either respective terminus. In any of the forgoing aspects or combinations, the protein substructures may include a linker, a capture sequence, or both, the linker covalently bonding the capture sequence to the protein substructure. Optionally, each of said protein substructures is identical in primary amino acid sequence. Optionally, each of said protein substructures comprises an amino acid sequence that is 70% or greater identical to any one of SEQ ID NOs: 1-6. In any of the forgoing aspects, one or more of the protein substructures optionally includes a capture sequence, the capture sequence expressed at or near the N-terminus of the protein substructure, the capture sequence comprising the sequence of SEQ ID NO: 8, SEQ ID NO: 9, biotin, or avidin. Optionally, one or more of the protein substructures includes a linker and a capture sequence, the linker covalently bonding the capture sequence to the protein substructure, the linker a flexible linker or a rigid linker. Optionally, a linker sequence has portions that are flexible and other portions that are rigid. A flexible linker optionally includes a multimer of the amino acid sequence GGS, GSS, or combinations thereof. A rigid linker optionally includes one or more stabilizing disulfide bonds, one or more repeats of SEQ ID NO: 10, an amino acid sequence comprising 3 or more proline residues, an amino acid sequence comprising 1 or more sequences of PPA, or a combination thereof. In any of the forgoing or combinations thereof, the multimeric self-assembling protein structure includes or is a multimer of any one of SEQ ID NOs: 1-6. Optionally, the multimer is a 60-mer. Optionally, the multimeric self-assembling protein structure forms a dodecahedron.

[0010] One power of the provided processes and the materials used therein is the ability to gather biological information, structural information, or both on a target protein that has a molecular weight of 200 kDa or less. As such, in any of the foregoing aspects the target protein has a molecular weight of less than 200 kDa, optionally less than 150 kDa, optionally less than 120 kDa. A target protein optionally includes a tag, the tag optionally complementary to a capture sequence such that an association between the tag and the capture sequence may result in a tight bond between the two, optionally a covalent bond. As such, tag optionally includes or is SEQ ID NO: 20, SEQ ID NO: 21, biotin, or avidin. While virtually any target protein sequence may be used in the processes as provided herein, optionally a target protein sequence is or includes the RNA-binding protein, cytosolic Poly-A Binding Protein (PABP) (optionally SEQ ID NO. 16), a DNA-binding protein of the ApiAP2 specific transcription factor family (optionally SEQ ID NO: 17), a binding domain of tristetraprolin (TTP) of a NOT family protein (optionally SEQ ID NO: 18), or a RNA-recognition motif of the Upregulated in Infectious Sporozoites 12 (UIS12) protein (optionally SEQ ID NO: 19). A target protein may be saturated onto a multimeric self-assembling protein structure, optionally at a saturation level of 50% or greater, optionally 90% or greater. While knowledge in the art dictated that visualizing protein by processes such as cryo-electron microcoscopy must be done using samples with a salt concentration of 100 mM or less, it was found that salt concentration is not limited in the provided processes. As such, the multimeric self-assembling protein structure forms a target complex in an aqueous buffer including at or greater than 100 mM of a salt, optionally greater than 200 mM salt, optionally, from 200 mM salt to 500 mM salt. Using any of the forgoing aspects, in a process as provided herein structural information may be obtained of a target protein by cryo-electron microscopy, optionally to a value of resolution less than 10 .ANG., optionally less than 5 .ANG., optionally less than 3 .ANG.. The value of resolution obtainable by the provided processes is sufficient to obtain biological or structural information of a target protein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] The aspects set forth in the drawings are illustrative and exemplary in nature and not intended to limit the subject matter defined by the claims. The following detailed description of the illustrative aspects can be understood when read in conjunction with the following drawings, where like structure is indicated with like reference numerals and in which:

[0012] FIG. 1A illustrates the selective binding of PyPABP1 to nanocages at various molar ratios of components;

[0013] FIG. 1B illustrates the selective binding of 2xAP2 to nanocages at various molar ratios of components;

[0014] FIG. 1C illustrates the selective binding of TTP to nanocages at various molar ratios of components;

[0015] FIG. 1D illustrates the selective binding of UIS12 to nanocages at various molar ratios of components;

[0016] FIG. 2A illustrates the empty nanocage with no linker or capture sequence at 7.64 .ANG. resolution by Cryo-EM;

[0017] FIG. 2B illustrates a zoomed in view of the empty nanocage of FIG. 2A illustrating resolvable secondary structure and substructure interaction;

[0018] FIG. 3 illustrates a Cryo-EM 3D reconstruction of a nanocage with a flexible 4xGGS linker positioned between the N-terminus of each substructure protein and a capture sequence;

[0019] FIG. 4 illustrates a Cryo-EM 3D reconstruction of a nanocage with a rigid 3xPPA linker positioned between the N-terminus of each substructure protein and a capture sequence; and

[0020] FIG. 5 illustrates a Cryo-EM 3D reconstruction of a nanocage with a flexible GGS linker positioned between the N-terminus of each substructure protein and a capture sequence with the nanocage with a resolution of 15 .ANG., bound to cytosolic Plasmodium yoelii Poly-A Binding Protein (PABP).

DETAILED DESCRIPTION

[0021] The following description of particular embodiment(s) is merely exemplary in nature and is in no way intended to limit the scope of the invention, its application, or uses, which may, of course, vary. The invention is described with relation to the non-limiting definitions and terminology included herein. These definitions and terminology are not designed to function as a limitation on the scope or practice of the invention but are presented for illustrative and descriptive purposes only. While the processes or compositions are described as an order of individual steps or using specific materials, it is appreciated that steps or materials may be interchangeable such that the description of the invention may include multiple parts or steps arranged in many ways as is readily appreciated by one of skill in the art.

[0022] It will be understood that, although the terms "first," "second," "third" etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, "a first element," "component," "region," "layer," or "section" discussed below could be termed a second (or other) element, component, region, layer, or section without departing from the teachings herein.

[0023] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms, including "at least one," unless the content clearly indicates otherwise. "Or" means "and/or." As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items. It will be further understood that the terms "comprises" and/or "comprising," or "includes" and/or "including" when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof. The term "or a combination thereof" means a combination including at least one of the foregoing elements.

[0024] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. It will be further understood that terms such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0025] A "protein" as used herein is an assembly of 2 or more amino acids linked by a peptide bond.

[0026] Provided are processes reagents that have utility for improved structure identification of target molecules. The processes capitalize on the power of cryo-electron microscopy (cryo-EM) and allow for structure solutions of target molecules having low molecular weights that were previously unsolvable by this method. By utilizing a relatively large and rigid protein structure that does not require genetic fusion with a target molecule, it was found that biological information can be solved with resolutions previously unattainable.

[0027] A process of solving a three-dimensional structure of a target protein as provided herein includes associating a target protein with a multimeric self-assembling protein structure (optionally non-naturally occurring) to form a target complex and subjecting the target complex to cryo-electron microscopy whereby the multimeric self-assembling protein structure serves as a scaffold for solution of the three-dimensional structure of the target protein. A multimeric protein structure as provided herein is a multimer of smaller proteins that assemble, optionally without the aid of external stimuli (self-assembling) to form the multimeric protein structure, optionally termed a "nanocage" in this disclosure. The smaller proteins are optionally protein substructures. The multimeric protein structure is the result of fusion of the protein substructures into a substantially rigid multimeric assembly suitable for use in cryo-electron microscopy.

[0028] The plurality of protein substructures self-assemble to form the multimeric protein structure. As is recognized in the art, self-assembly is the oligomerization of protein substructures into an ordered arrangement driven by non-covalent interactions. Such non-covalent interactions may be any of electrostatic interactions, .pi.-interactions, van der Walls forces, hydrogen bonding, hydrophobic effects, or any combination thereof. The resulting multimeric protein structure is optionally ordered into a shape, illustratively an icosahedron, but others may be used as well such as those with tetrahedral or octahedral symmetry. Illustrative examples of such multimeric protein structures and how to make them are illustrated in WO 2016/138525 and U.S. Patent Application Publication No: 2015/0356240.

[0029] The number of protein substructures in a multimeric protein assembly is dependent on the overall arrangement. In some aspects, the number of protein substructures is 60 forming an icosahedron, however other structures with different numbers of substructures are similarly useful such as 24 protein subunit structures illustratively as that described by King, et al., Nature, 510, 103-108 (2014), or 12 protein subunit structures such as that described by King, et al., Science, 336, 1171-1174 (2012), 4-protein subunit structures illustratively as that described by Liu et al. Proceedings of the National Academy of the Sciences (in press) doi:http://dx.doi.org/10.1101/212233.

[0030] It is appreciated that in some aspects all protein substructures may be identical in primary sequence thereby promoting identity in structure to form a homomultimeric protein structure. However, there may be some structures where two or more different protein substructures are used. Optionally, 2, 3, 4, 5, or more different protein substructures may be used to form the multimeric protein structure.

[0031] Optionally, the protein substructures are forms of aldolase protein, optionally structurally modified so as to either alter self-assembly properties, increase rigidity of the final multimeric structure, to express one or more tags for purification, to express one or more tags for associating with a target protein or combinations thereof. In some aspects, the protein substructures are one or more of those described by Hsia, et al., Nature, 2016; 535:136-147 or those designed and described in WO 2016/138525A1 with either optionally modified otherwise as described herein.

[0032] Optionally, a protein substructure includes the primary sequence as defined in SEQ ID NO: 1 (MEELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADTVIKELSFLKEM GAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKA MKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGV GSALVKGTPVEVAEKAKAFVEKTRGCTEHM), optionally SEQ ID NO 2 (MEELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADTVIKELSFLKEM GAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKA MKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGV GSALVKGTPVEVAEKAKAFVEKIRGCTEHM), optionally SEQ ID NO: 3 (FKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADTVIKELSFLKEMGAIIG AGTVTSVEQCRKAVESGAEFIVSPILDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGI TILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALV KGTPVEVAEKAKAFVEKIRGCTEHM). In some aspects, a protein substructure further includes additional residues at an N or C terminus that may be due to translations from endonuclease restriction sites, tags such as for purification (e.g. 6xHis tag), a specific protease cleavage site such as a thrombin cleavage site, or other suitable modification. In some aspects, the protein substructures include the primary sequence of SEQ ID NO: 4 (MKMEELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADTVIKELSFLK EMGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVK AMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVG VGSALVKGTPVEVAEKAKAFVEKIRGCTEHM), SEQ ID NO: 5 (ASMEELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADTVIKELSFLKE MGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVK AMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVG VGSALVKGTPVEVAEKAKAFVEKIRGCTEHM) or SEQ ID NO: 6 (EELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADTVIKELSFLKEMG AIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAM KLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVG SAIVKGTPVEVAEKAKAFVEKIRGCTEHM).

[0033] The protein substructures are optionally modified at one or more amino acid positions relative to any one or more of SEQ ID Nos: 1-6. Optionally, the protein substructures are 70% identical or greater to any one or more of SEQ ID Nos: 1-6, optionally 75% or more identical, optionally 80% or more identical, optionally 85% or more identical, optionally 90% or more identical, optionally 95% or more identical, optionally 96% or more identical, optionally 97% or more identical, optionally 98% or more identical, optionally 99% or more identical. Illustrative residues that may be substituted include E26K, E33L, K61M, D187V and R190A. Optionally, other substitutions may be made such as deletion of any of the first 10 residues at the N- or C-termini of the protein substructures. In some aspects, an extra M is added to the N-terminus so as to extend the alpha helical structure, optionally into an alpha helical linker as described herein.

[0034] Modifications and changes can be made in the structure of the protein substructure primary sequences that are the subject of the application and still obtain a molecule having similar characteristics as the original such as similar self-assembly properties, similar rigidity to the final multimeric structure, or other. Such substitutions are optionally conservative amino acid substitutions. For example, certain amino acids can be substituted for other amino acids in a sequence without appreciable alteration of desired properties. Because it is the interactive capacity and nature of a polypeptide that defines that polypeptide's biological functional activity, certain amino acid sequence substitutions can be made in a polypeptide sequence and nevertheless obtain a polypeptide with like properties.

[0035] In making such changes, the hydropathic index of amino acids can be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a polypeptide is generally understood in the art. It is known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still result in a polypeptide with similar biological activity. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. Those indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cysteine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3), proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5), asparagine (-3.5); lysine (-3.9); and arginine (4.5).

[0036] It is believed that the relative hydropathic character of the amino acid determines the secondary structure of the resultant polypeptide, which in turn defines the interaction of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, and the like. It is known in the art that an amino acid can be substituted by another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such changes, the substitution of amino acids whose hydropathic indices are within .+-.2 are optional, those within .+-.1 are optional preferred, and those within .+-.0.5 are optional.

[0037] Substitution of like amino acids can also be made on the basis of hydrophilicity, particularly, where the biological functional equivalent polypeptide or peptide thereby created is intended for use in particular aspects as described herein. The following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0.+-.1); glutamate (+3.0.+-.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); proline (-0.5.+-.1); threonine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent polypeptide. In such changes, the substitution of amino acids whose hydrophilicity values are within .+-.2 is preferred, those within .+-.1 are particularly preferred, and those within +0.5 are even more particularly preferred.

[0038] As outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include (original residue: exemplary substitution): (Ala: Gly, Ser), (Arg: Lys), (Asn: Gln, His), (Asp: Glu, Cys, Ser), (Gln: Asn), (Glu: Asp), (Gly: Ala), (His: Asn, Gln), (Ile: Leu, Val), (Leu: Ile, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), (Tip: Tyr), (Tyr: Trp, Phe), and (Val: Ile, Leu). Aspects of this disclosure thus contemplate functional or biological equivalents of a polypeptide as set forth above. In particular, aspects of the polypeptides can include variants having about 50%, 60%, 70%, 80%, 90%, and 95% sequence identity to the polypeptide of interest.

[0039] One or more of the protein substructures is optionally modified at the N-terminus, the C-terminus or both with one or more of a linker, a capture sequence, or both. One power of the present invention is the ability to create self-assembling proteins structures that express capture sequences oriented either out and away from the multimeric structure such as through an N-terminal capture sequence, directed into the core of the multimeric structure such as through a C-terminal capture sequence or both. A capture sequence may be located directly at the N- or C-terminus, or within 10 amino acids from the N- or C-terminus, optionally in substitution of or within 10 amino acids of the N- or C-terminus of any one or more of SEQ ID Nos: 1-6.

[0040] One advantage of a capture sequence is that it eliminates the need for genetic fusions of target proteins-of-interest for construction of the multimeric self-assembling protein structure. For example, prior preparations of nanocages with a protein used as a label required that the monomers be recombinantly expressed already fused to the target protein-of-interest, increasing complexity of making the materials as well as reducing the likelihood of success. The use of a capture sequence that can pair with a tag sequence on a target protein-of-interest increases the robustness of the resulting nanocage, but also allows for adjustment of parameters such as saturation of target protein on the nanocage that were found to improve the resulting overall structure solution by cryo-electron microscopy.

[0041] As such, a protein substructure optionally includes one or more capture sequences. Illustrative examples of a capture sequence include those that allow specific recognition of the capture sequence by the tag on the target protein and lead to covalent bonding of the two, optionally through the use of a spontaneous isopeptide bond. Optionally, a tag terminates with an alkylamine or other functional group that can pair with a tag on a target sequence. Optionally, the tag on the target sequence terminates in a carboxylic acid allowing isopeptide bond formation with the capture sequence. This results in robust covalent bonding between the nanocage and the target protein of interest.

[0042] In some aspects, a capture sequence is or includes biotin, avidin, SEQ ID NO: 7 (GSGDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDFYLYPGKYTFVE TAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIGVD), SEQ ID NO. 8 (MGSSHHHHHHGSGDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDF YLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIGVD), SEQ ID NO: 9 (MKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFKNLSDGKYRLFENS EPAGYKPVQNKPIVAFQIVNGEVRDVTSIVPQDIPATYEFTNGKHYITNEPIPPK), any functional portion thereof, a nucleic acid (e.g., deoxyribonucleic acid, or ribonucleic acid) sequence, or other such suitable capture sequence. A suitable capture sequence is one that will bind, either covalently or non-covalently, and specifically with a tag or other desired portion of a target molecule.

[0043] In some aspects one or more protein substructure of a multimeric self-assembling protein structure includes a linker, the linker bound to the protein substructure and the capture sequence, optionally between the protein substructure and the capture sequence. The linker optionally covalently or non-covalently (e.g. hydrogen bonding, van der Walls forces, hydrophobic effects, electrostatic interactions, n-interactions, or combinations thereof), or both, binds the protein substructure to the capture sequence.

[0044] A linker is optionally a protein linker, single amino acid, nucleic acid based linker such as one or more nucleotides (e.g., ribonucleotides, deoxyribonucleotide), a nucleic acid of two or more nucleotides, a substituted or unsubstituted alkyl, akenyl, or alkynyl of 1-20 carbons, or other suitable structure. Optionally, a linker is a flexible linker or a rigid linker. A flexible linker is one that is not restricted by interlinker bonding or regular three dimensional structure in an aqueous environment at 25.degree. C. A rigid linker is one that includes one or more interlinker bonds (either covalent or non-covalent) (e.g. electrostatic interaction, disulfide bond, or other) or forms a secondary structure (e.g. alpha helix, beta sheet, beta turn, omega loop) that is stable in an aqueous environment at 25.degree. C.

[0045] Optionally, a linker is a protein linker of two or more amino acids. Illustrative protein linkers include, but are not limited to one or more multimers of the sequence GGS, GSS, PPA, SEQ ID NO: 10, a proline residue, or combinations thereof. A multimer of any of the forgoing optionally include 2, 3, 4, 5, 6, 7, 8, 9, or more repeats or substitutions of the foregoing. In specific examples, a linker has a sequence of 5 repeats of GGS, 5 repeats of GSS, 5 or more linked GGS and GSS sequences in any order, 5 repeats of SEQ ID NO: 10, a 9-mer of proline residues, a 3-mer of the sequence PPA, or any combination thereof.

[0046] As such, a protein substructure optionally includes a self-assembling monomer protein, a linker, and a capture sequence where the linker and the capture sequence are optionally bound to the self-assembling monomer at the N-terminus, the C-terminus, or both. Illustrative examples of protein substructures include but are not limited to those of SEQ ID NO: 11 (MGSSHHHHHHGSGDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDF YLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIGVDHHHHHHG GSGGSGGSGGSMKMEELFKKHIKIVAVLRANSVEEAKKKALAVFLGGVIILIEITFTVPDA DTVIKELSFLKEMGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMP GVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCE WFKAGVLAVGVGSALVKGTPVEVAEKAKAFVEKIRGCTEHM), SEQ ID NO: 12 (MGSSHHHHHHGSGDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDF YLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIGVDEAAAKEAA AKEAAAKEAAAKEAAAKASMEELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEI TFTVPDADTVIKELSFLKEMGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKE KGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGV NLDNVCEWFKAGVLAVGVGSALVKGTPVEVAEKAKAFVEKIRGCTEHM), SEQ ID NO: (MGSSHHHHHHGSGDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDF YLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIGVDEAAAKEAA AKEAAAKEAAAKEAAAKEELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFT VPDADTVIKELSFLKEMGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGV FYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDN VCEWFKAGVLAVGVGSALVKGTPVEVAEKAKAFVEKIRGCTEHM), SEQ ID NO: 14 (MGSSHHHHHHGSGDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDF YLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIGVDPPPPPPPPP EELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEIIFTVPDADTVIKELSFLKEMGA IIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKL GHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSA LVKGTPVEVAEKAKAFVEKIRGCTEHM), or SEQ ID NO: 15 (MGSSHHHHHHGSGDSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDF YLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIGVDPPAPPAPPA EELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADTVIKELSFLKEMGA IIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKL GHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSA LVKGTPVEVAEKAKAFVEKIRGCTEHM). It is appreciated based on the teachings provided herein and the skill of one in the art that modifications of any of the aforementioned sequences are similarly suitable. Illustratively, a protein substructure is optionally 70% or more identical to any one of SEQ ID Nos: 11-15, optionally 80% or more identical to any one of SEQ ID Nos: 11-15, optionally 90% or more identical to any one of SEQ ID Nos: 11-15, optionally 95% or more identical to any one of SEQ ID Nos: 11-15, optionally 96% or more identical to any one of SEQ ID Nos: 11-15, optionally 97% or more identical to any one of SEQ ID Nos: 11-15, optionally 98% or more identical to any one of SEQ ID Nos. 11-15, optionally 99% or more identical to any one of SEQ ID Nos: 11-15.

[0047] A multimeric self-assembling protein structure that expresses a capture sequence is capable of binding, optionally specifically binding, a target protein. Due to the rigidity and regularity of the multimeric self-assembling protein structure, the compositions and processes are able to provide biological or structural information of a target protein when analyzed by cryo-electron microscopy. Cryo-electron microscopy is undergoing a sea change in its ability to deliver such biological and structural information concerning a protein of interest. Atomic resolution structures with low or no symmetry now represent the fastest growing group of structures submitted to the EM database. The vast majority of these structures, however, have a molecular weight of 200 kilodaltons (kDa) or greater. The molecular mass size restriction of >200 kDa for successful cryo-EM structures achieved previously is largely due to the high noise and low contrast of unstained biological samples embedded in vitrified buffer. It was found by the inventors of this disclosure that the use of multimeric self-assembling protein structures as provided herein are capable of delivering resolution (20 .ANG.) information of molecules with a molecular mass of less than 200 kDa.

[0048] As such, a target protein as used in the processes or compositions as provided herein is optionally a protein with a molecular weight in kDa at or less than 200, optionally 190, optionally 180, optionally 170, optionally 160, optionally 150, optionally 140, optionally 130, optionally 120, optionally 110, optionally 100, or lower. In specific aspects, a target protein has a molecular weight of 150 kDa or less. In other aspects, a target protein has a molecular weight of 120 kDa or less. It is appreciated that the molecular weight of a target protein as used herein is the calculated molecular weight of the protein free of post translational modifications such as glycosylation, phosphorylation, sulfonation, or other. The molecular weight of a target protein as used herein is the molecular weight absent a tag, purification sequence, or both.

[0049] Illustrative specific examples of target proteins include those of the RNA-binding protein, cytosolic Poly-A Binding Protein (PABP), a DNA-binding protein of the ApiAP2 specific transcription factor family, a binding domain of tristetraprolin (TTP) of a NOT family protein, or a RNA-recognition motif of the Upregulated in Infectious Sporozoites 12 (UIS12) protein, among others. It is appreciated that the identity, primary sequence, secondary structure, tertiary structure, posttranslational modification, or function of a target protein is independent of the ability of the processes as provided herein to provide biological or structural information about the structural protein by cryo-electron microscopy.

[0050] Specific examples of target proteins are those provided in SEQ ID NO: 16 (MTMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFE TLKVDFLSKLPEMLKMFEDRLCIKTYLNGDIIVTHPDFMLYDALDVVLYMDPMCLDAF PKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSSMGMIA NSTNIMPPSFSTASLYVGDLSEDVTEAVLYEIFNTVGHVLSIRVCRDSVTRKSLGYAYVN YHNLADAERALDTLNYTNIKGQPARLMWSHRDPSLRKSGTGNIFVKNLDKTIDNKALF DTFSMFGNILSCKVATDEFGKSKNYGFVHYEDEESAKEAIEKVNGMQLGSKNVYVGHFI KKSERATNDTKFTNLYVKNFPDTVTEAHLKQLFSPYGEITSMIVKSDNKNRKFCFINYSD ADSARNAMENLNGKKITEDGKIDYNYDPKKEETEKPANENSNNNTTTEENTTTSETPAE KKTPDSEPATNKDATPGEDQTSANGTTTTVTSTTDANPDSKTEETPNDNTANAGTNAST TEKKDNKKSGENTETPNILYVGPHQSRARRHAILKAKFDTLNTESRNKHPGVNLYIKNL DDSMNDQTLKELFEPYGTITSAKVMKDDKDQSKGFGFVCFGTHEEANKAVTEMHLKII NGKPLYVGLAEKREQRLSRLQQRFRMHPIRHHINNALNAPIQYPNSQTAQLQFNQNTLN YGRPVITSFNQNNLISW RHQQAAAQQQAAHQQAAAQQQLGFNGGLRGQINQMRLYTQ NNMINHNIGQNKANQQLHHNQQYPIGPNPQHQQTNLNAPAQTNPQQLQGAAPVPTNQL LNNNMRNMNSRGNRNLPGINIQSPKQMPLNMVGAKQTNPQQNQPQNQPQNQPQGQPQ NQPQQKSGQSIQQQQQQQQQQTIPQNNNFKFTSQARNRMELPNKNGNKVNNMTPGYN NNTTLTAAALASAPPSMQKQVLGENLFPLVANYHPTLAGKITGMMLEMDNSELLILLEN EDQLKKKIDEALAVLQNAK), SEQ ID NO: 17 (IGSQEPVILIDKIERCLVVEWYENNIRREQRISYKKYGNDKAKLRAKELIEKLKSGITFEQ IYPDKGPPIVRVFENVGVYNVSITRDRITERFWRVEWLFNGVPMKARWSCKK VGNDE AQ KRADTFAQSMIKGIFNP), SEQ ID NO: 18 (NNNFNINLQIEDGITNKYEAEVNGYFAKLYTGEITVNTMIDIMKNLSCSPKGSKNNDIYK SMLLILFNECKFFPKYPVEELDITAQLFGKLIKHNLLISYGNTLSVVLKCILEALKKGSDS KVFNFGITALEQFEDSLICYPAFLSSLIPLPTLRQYNPQYIIHCNELLNTLPEQFRTLPYIDA STILKIKHISEISS), SEQ ID NO: 19 (KNVIITNVFLGNIPPNITEERLKNVLEIFGYIIHIIEYKW SLDKWSYAFIYFIEEKCAINA VNI LNQKKFFDNSPNHKLICFIVSKQIPNQNTLHYSKANFSLLKDGPPGANLFLYGIPLKWTE LNLIQLVNKYGHVVGLRIPYINNDNDKKQGNRGFGFVSYDNKKSAVEAFEELSKMYIH GKLLKVQLKNGEE), or other sequence, or modification thereof.

[0051] The target protein optionally is a modification of a wild-type sequence such that the target protein is non-naturally occurring. Such modifications include the addition, subtraction or substitution or one or more amino acids optionally for the purpose of including an endonuclease restriction site, a site to add or remove a post-translational modification, or a tag for purification or labeling purposes (e.g. 6xHis tag, GST tag, addition of a fluorophore, etc.), among other reasons known in the art for protein identification, labeling, localization, purification, etc.

[0052] A target protein optionally includes one or more tags that are complementary to a capture sequence on a substructure protein. Complementary in this sense means that the tag will bind to, optionally specifically bind to, the capture sequence, optionally with high affinity. The specific localization of the target protein to the capture sequence allows the use of the resulting complex in cryo-electron microscopy to gather biological or structural information about the target protein. A target protein optionally includes 1 tag, optionally 2 or more tags. A tag is optionally a multimeric or repeating amino acid or nucleic acid sequence, a vitamin, or other suitable tag sequence. Illustrative examples of a tag on a target protein includes but are not limited to avidin, biotin, SEQ ID NO: 20 (AHIVMVDAYKPTK), or SEQ ID NO: 21 (KLGDIEFIKVNKG). It should be recognized that SEQ ID NO: 20 is a complementary tag to the capture sequence of SEQ ID NO: 7 in that the two sequences will self-associate to form a complex that is then auto-linked by a covalent bond between a lysine on one unit and an aspartic acid on the other unit to form an isopeptide bond. Similarly, tag sequence SEQ ID NO. 21 is complementary to capture sequence SEQ ID NO: 9 where a complex is formed that results in the formation of a covalent linkage between the tag and the capture sequence. Similar and specific high affinity interactions are optionally observed between avidin and biotin where a substructure protein is labeled with either avidin or biotin, and the target protein is labeled with the complementary tag of either biotin or avidin.

[0053] A target protein optionally includes 1 tag, optionally 2 tags, optionally 3 tags. A tag is optionally localized to an N-terminal end, a C-terminal end, an intermediate position, or other. Optionally, a target protein is expressed with one or more tags within the peptide sequence and is exposed at the N-terminal end or C-terminal end by cleavage of a portion of the protein sequence by a protease.

[0054] Target proteins, similar to substructure proteins, are optionally produced by recombinant DNA expression efforts as recognized in the art. As such, a target protein sequence optionally includes one or more of an extra amino acid or multiple amino acids resulting from the insertion of a restriction endonuclease cleave site in the DNA, one or more protease cleavage sites, and one or more purification tags. A target protein may be coexpressed with associated purification tags, modifications, other proteins such as in a fusion peptide, or other modifications or combinations as recognized in the art. Illustrative purification tags include 6xHis, FLAG, biotin, ubiquitin, SUMO, or other tag known in the art. A purification tag is illustratively cleavable such as by linking to a target protein via an enzyme cleavage sequence that is cleavable by an enzyme known in the art illustratively including Factor Xa, thrombin, SUMOstar protein, or trypsin. It is further appreciated that chemical cleavage is similarly operable with an appropriate cleavable linker.

[0055] Illustrative specific examples of target proteins as expressed by recombinant DNA efforts include for illustration purposes only and are not limited to SEQ ID NO: 22 (MTMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFE TLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAF PKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSSMGMIA NSTNIMPPSFSTASLYVGDLSEDVTEAVLYEIFNTVGHVLSIRVCRDSVTRKSLGYAYVN YHNLADAERALDTLNYTNIKGQPARLMWSHRDPSLRKSGTGNIFVKNLDKTiDNKALF DTFSMFGNILSCKVATDEFGKSKNYGFVHYEDEESAKEAIEKVNGMQLGSKNVYVGHFI KKSERATNDTKFTNLYVKNFPDTVTEAHLKQLFSPYGEITSMIVKSDNKNRKFCFINYSD ADSARNAMENLNGKKITEDGKIDYNYDPKKEETEKPANENSNNNTTTEENTTTSETPAE KKTPDSEPATNKDATPGEDQTSANGTTTTVTSTTDANPDSKTEETPNDNTANAGTNAST TEKKDNKKSGENTETPNILYVGPHQSRARRHAILKAKFDTLNTESRNKHPGVNLYIKNL DDSMNDQTLKELFEPYGTITSAKVMKDDKDQSKGFGFVCFGTHEEANKAVTEMHLKII NGKPLYVGLAEKREQRLSRLQQRFRMHPIRHHINNALNAPIQYPNSQTAQLQFNQNTLN YGRPVITSFNQNNLISWRHQQAAAQQQAAHQQAAAQQQLGFNGGLRGQINQMRLYTQ NNMINHNIGQNKANQQLHHNQQYPIGPNPQHQQTNLNAPAQTNPQQLQGAAPVPTNQL LNNNMRNMNSRGNRNLPGINIQSPKQMPLNMVGAKQTNPQQNQPQNQPQNQPQGQPQ NQPQQKSGQSIQQQQQQQQQQTIPQNNNFKFTSQARNRMELPNKNGNKVNNMTPGYN NNTTLTAAALASAPPSMQKQVLGENLFPLVANYHPTLAGKITGMMLEMDNSELILLEN EDQLKKKIDEALAVLQNAKLEAHIVMVDAYKPIKVENLYFQGVEHHHHHH), SEQ ID NO: 23 (MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYI DGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLK VDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKL VCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDIHPPKSDLVPRGSIISAIIIVMVD AYKPTKAMIGSQEPVILIDKIERCLVVEWYENNIRREQRISYKKYGNDKAKLRAKELIEK LKSGITFEQLYPDKGPPIVRVFENVGVYNVSLIRDRIEREWRVEWLENGVPMKARWSCK KVGNDEAQKRADTFAQSMIKGIFNP), SEQ ID NO: 24 (MTMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFE TLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAF PKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSSMGSSH HHHHHSSGLVPRGSHIAHIVMVDAYKPTKHMNNNFNINLQIEDGITNKYEAEVNGYFAK LYTGEITVNTMIDIMKNLSCSPKGSKNNDIYKSMLLILFNECKFFPKYPVEELDITAQLFG KLIKHNLLISYGNTLSVVLKCILEALKKGSDSKVFNFGITALEQFEDSLICYPAFLSSLIPLP TLRQYNPQYIIHCNELLNTLPEQFRTLPYIDASTILKIKHISEISS), SEQ ID NO: 25 (MTMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFE TLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAF PKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSSMGSSH HHHHHSSGLVPRGSHIAHIVMVDAYKPTKHMKNVIITNVFLGNIPPNITEERLKNVLEIFG YIIHIEYKWSLDKWSYAFIYFIEEKCAINAVNILNQKKFFDNSPNHKLICFIVSKQIPNQNT LHYSKANFSILLKDGPPGANLFLYGTPLKWTELNLTQIVNKYGHVVGLRIPYINNDNDKK QGNRGFGFVSYDNKKSAVEAFEELSKMYIHGKLLKVQLKNGEELENLYFQGVEHHHHH H). It is appreciated that modifications of any of the forgoing such as by substitution of a tag, a purification tag, localization of a tag, a purification tag, or protease cleave site are well within the level of skill in the art and presented under this disclosure. Any of the aforementioned substitutions of amino acids above are equally applicable to a target protein and incorporated herein by reference.

[0056] A substructure protein, target protein, or any portion thereof, optionally further including a purification tag, linker, capture sequence, protease cleavage site, or other, are optionally formed by recombinant DNA expression methods. The identification of codon sequences in DNA/RNA from a known protein sequence are readily achieved by persons of ordinary skill in the art. Protein expression is illustratively accomplished from transcription of desired nucleic acid sequence, translation of RNA transcribed from desired nucleic acid sequence, modifications thereof, or fragments thereof. Protein expression is optionally performed in a cell based system such as in E. coli, HeLa cells, or Chinese hamster ovary cells. Bacterial cells such as E. coli are commonly used, but if post-translational modifications are desired on one or more of a target protein, protein substructure or both may be expressed in a mammalian cell. It is appreciated that cell-free expression systems are similarly operable.

[0057] It is recognized that numerous variants, analogues, or homologues are within the scope of the present invention including amino acid substitutions, alterations, modifications, or other amino acid changes that increase, decrease, or do not alter the function of the substructure protein sequence or target protein sequence. Several post-translational modifications are similarly envisioned as within the scope of the present invention illustratively including incorporation of a non-naturally occurring amino acid, phosphorylation, glycosylation, addition of pendent groups such as biotinylation, fluorophores, lumiphores, radioactive groups, antigens, or other molecules.

[0058] A method is also provided for recombinantly expressing a protein substructure or target protein nucleic acid or protein sequence or fragments thereof wherein a cell is transformed with a desired nucleic acid sequence and cultured under suitable conditions that permit expression of the protein substructure or target protein nucleic acid sequence or protein either within the cell or secreted from the cell. Cell culture conditions are particular to cell type and expression vector. Culture conditions for particular vectors and cell types are within the level of skill in the art to design and implement without undue experimentation.

[0059] Recombinant or non-recombinant proteinase peptides or recombinant or non-recombinant proteinase inhibitor peptides or other non-peptide proteinase inhibitors can also be used in the expression of a substructure protein or target protein. Proteinase inhibitors are optionally modified to resist degradation, for example degradation by digestive enzymes and conditions. Techniques for the expression and purification of recombinant proteins are known in the art (see Sambrook Eds., Molecular Cloning: A Laboratory Manual 3.sup.rd ed. (Cold Spring Harbor, N.Y. 2001).

[0060] Some aspects of the present invention are compositions containing protein substructure (e.g., I3-01 substructure protein) or target protein nucleic acid that can be expressed as encoded polypeptides or proteins. The engineering of DNA segment(s) for expression in a prokaryotic or eukaryotic system may be performed by techniques generally known to those of skill in recombinant expression. It is believed that virtually any expression system may be employed in the expression of the claimed nucleic and amino sequences.

[0061] Generally speaking, it may be more convenient to employ as the recombinant polynucleotide a cDNA version of the polynucleotide. It is believed that the use of a cDNA version will provide advantages in that the size of the gene will generally be much smaller and more readily employed to transfect the targeted cell than will a genomic gene, which will typically be up to an order of magnitude larger than the cDNA gene. However, the inventor does not exclude the possibility of employing a genomic version of a particular gene (e.g. target protein) where desired.

[0062] As used herein, the terms "engineered" and "recombinant" cells are synonymous with "host" cells and are intended to refer to a cell into which an exogenous DNA segment or gene, such as a cDNA or gene has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells that do not contain a recombinantly introduced exogenous DNA segment or gene. A host cell is optionally a naturally occurring cell that is transformed with an exogenous DNA segment or gene or a cell that is not modified. A host cell preferably does not possess a naturally occurring gene encoding or similar to a target protein or protein substructure. Engineered cells are thus cells having a gene or genes introduced through the hand of man. Recombinant cells include those having an introduced cDNA or genomic DNA, and also include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene.

[0063] To express a recombinant encoded polypeptide in accordance with the present invention one would prepare an expression vector that comprises a polynucleotide under the control of one or more promoters. To bring a coding sequence "under the control of" a promoter, one positions the 5' end of the translational initiation site of the reading frame generally between about 1 and 50 nucleotides "downstream" of (i.e., 3' of) the chosen promoter. The "upstream" promoter stimulates transcription of the inserted DNA and promotes expression of the encoded recombinant protein. This is the meaning of "recombinant expression" in the context used here.

[0064] Many standard techniques are available to construct expression vectors containing the appropriate nucleic acids and transcriptional/translational control sequences in order to achieve protein or peptide expression in a variety of host-expression systems. Cell types available for expression include, but are not limited to, bacteria, such as E. coli and B. subtilis transformed with recombinant phage DNA, plasmid DNA or cosmid DNA expression vectors.

[0065] Certain examples of prokaryotic hosts are E. coli strain RR1, E. coli LE392, E. coli B, E. coli.chi. 1776 (ATCC No. 31537) as well as E. coli W3110 (F-, lambda-, prototrophic, ATCC No. 273325); bacilli such as Bacillus subtilis; and other enterobacteriaceae such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas species.

[0066] In general, plasmid vectors containing replicon and control sequences that are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences that are capable of providing phenotypic selection in transformed cells. For example, E. coli is often transformed using pBR322, a plasmid derived from an E. coli species. Plasmid pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters that can be used by the microbial organism for expression of its own proteins.

[0067] In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda may be utilized in making a recombinant phage vector that can be used to transform host cells, such as E. coli LE392.

[0068] Further useful vectors include pIN vectors and pGEX vectors, for use in generating glutathione S-transferase (GST) soluble fusion proteins for later purification and separation or cleavage. Other suitable fusion proteins are those with .beta.-galactosidase, ubiquitin, or the like.

[0069] Promoters that are most commonly used in recombinant DNA construction include the .beta.-lactamase (penicillinase), lactose and tryptophan (trp) promoter systems. While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling those of skill in the art to ligate them functionally with plasmid vectors.

[0070] For expression in Saccharomyces, the plasmid YRp7, for example, is commonly used. This plasmid contains the trp1 gene, which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1. The presence of the trp1 lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

[0071] Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression vector 3' of the sequence desired to be expressed to provide polyadenylation of the mRNA and termination.

[0072] Other suitable promoters, which have the additional advantage of transcription controlled by growth conditions, include the promoter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization.

[0073] In addition to microorganisms, cultures of cells derived from multicellular organisms may also be used as hosts. In principle, any such cell culture is operable, whether from vertebrate or invertebrate culture. In addition to mammalian cells, these include insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus); and plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing one or more coding sequences.

[0074] In a useful insect system, Autographica californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The isolated nucleic acid coding sequences are cloned into non-essential regions (for example the polyhedron gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedron promoter). Successful insertion of the coding sequences results in the inactivation of the polyhedron gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedron gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed (e.g., U.S. Pat. No. 4,215,051).

[0075] Examples of useful mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, W138, BHK, COS-7, 293, HepG2, NIH3T3, RIN and MDCK cell lines. In addition, a host cell may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the encoded protein.

[0076] Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. Expression vectors for use in mammalian cells ordinarily include an origin of replication (as necessary), a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences. The origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

[0077] The promoters may be derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Further, it is also possible, and may be desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.

[0078] A number of viral based expression systems may be utilized, for example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40 (SV40). The early and late promoters of SV40 virus are useful because both are obtained easily from the virus as a fragment that also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the HindIII site toward the BglI site located in the viral origin of replication.

[0079] In cases where an adenovirus is used as an expression vector, the coding sequences may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing proteins in infected hosts.

[0080] Specific initiation signals may also be required for efficient translation of the claimed isolated nucleic acid coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may additionally need to be provided. One of ordinary skill in the art would readily be capable of determining this need and providing the necessary signals. It is well known that the initiation codon must be in-frame (or in-phase) with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements or transcription terminators.

[0081] In eukaryotic expression, one will also typically desire to incorporate into the transcriptional unit an appropriate polyadenylation site if one was not contained within the original cloned segment. Typically, the poly(A) addition site is placed about 30 to 2000 nucleotides "downstream" of the termination site of the protein at a position prior to transcription termination.

[0082] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines that stably express constructs encoding proteins may be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with vectors controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched medium, and then are switched to a selective medium. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci, which in turn can be cloned and expanded into cell lines.

[0083] A number of selection systems may be used, including, but not limited, to the herpes simplex virus thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyltransferase genes, in tk.sup.-, hgprt.sup.- or aprt.sup.- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate; gpt, which confers resistance to mycophenolic acid; neo, which confers resistance to the aminoglycoside G-418, and hygro, which confers resistance to hygromycin. It is appreciated that numerous other selection systems are known in the art that are similarly operable in the present invention.

[0084] It is contemplated that the isolated nucleic acids of the disclosure may be "overexpressed", i.e., expressed in increased levels relative to its natural expression in cells of its indigenous organism, or even relative to the expression of other proteins in the recombinant host cell. Such overexpression may be assessed by a variety of methods, including radio-labeling and/or protein purification. However, simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or immunoblotting, followed by quantitative analyses, such as densitometric scanning of the resultant gel or blot. A specific increase in the level of the recombinant protein or peptide in comparison to the level in natural human cells is indicative of overexpression, as is a relative abundance of the specific protein in relation to the other proteins produced by the host cell and, e.g., visible on a gel.

[0085] Further aspects of the present disclosure concern the purification, and in particular embodiments, the substantial purification, of an encoded protein or peptide. The term "purified" or "isolated" protein or peptide as used herein, is intended to refer to a composition, isolatable from other components, wherein the protein or peptide is purified to any degree relative to its naturally-obtainable state, i.e., in this case, relative to its purity within a cell of a tick salivary gland. A purified protein or peptide therefore also refers to a protein or peptide, free from the environment in which it may naturally occur.

[0086] Generally, "purified" or "isolated" will refer to a protein or peptide composition that has been subjected to fractionation to remove various other components, and which composition substantially retains its expressed biological activity. Where the term "substantially" purified is used, this designation will refer to a composition in which the protein or peptide forms the major component of the composition, such as constituting about 50% or more of the proteins in the composition.

[0087] Various methods for quantifying the degree of purification of the protein or peptide will be known to those of skill in the art in light of the present disclosure as based on knowledge in the art. These include, for example, determining the specific activity of an active fraction, or assessing the number of polypeptides within a fraction by SDS/PAGE analysis. A preferred method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity, herein assessed by a "-fold purification number". The actual units used to represent the amount of activity will, of course, be dependent upon the particular assay technique chosen to follow the purification and whether or not the expressed protein or peptide exhibits a detectable activity.

[0088] Various techniques suitable for use in protein purification will be well known to those of skill in the art. These include, for example, precipitation with ammonium sulfate, polyethylene glycol, antibodies and the like or by heat denaturation, followed by centrifugation; chromatography steps such as ion exchange, gel filtration, reverse phase, hydroxylapatite and affinity chromatography; isoelectric focusing; gel electrophoresis; and combinations of such and other techniques. As is generally known in the art, it is believed that the order of conducting the various purification steps may be changed, or that certain steps may be omitted, and still result in a suitable method for the preparation of a substantially purified protein or peptide.

[0089] There is no general requirement that the protein or peptide always be provided in their most purified state. Indeed, it is contemplated that less substantially purified products will have utility in certain embodiments. Partial purification may be accomplished by using fewer purification steps in combination, or by utilizing different forms of the same general purification scheme. For example, it is appreciated that a cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater-fold purification than the same technique utilizing a low pressure chromatography system. Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein.

[0090] It is known that the migration of a polypeptide can vary, sometimes significantly, with different conditions of SDS/PAGE (Capaldi et al., Biochem. Biophys. Res. Comm., 76:425, 1977). It will therefore be appreciated that under differing electrophoresis conditions, the apparent molecular weights of purified or partially purified expression products may vary.

[0091] Methods of obtaining a target protein or protein substructure illustratively include isolation of target protein or protein substructure from a host cell or host cell medium. Methods of protein isolation illustratively include column chromatography, affinity chromatography, gel electrophoresis, filtration, or other methods known in the art. Optionally, target protein or protein substructure is expressed with a tag operable for affinity purification. As described above, optionally, a purification tag is a 6x His tag. A 6x His tagged protein is illustratively purified by Ni-NTA column chromatography or using an anti-6x His tag antibody fused to a solid support. (Geneway Biogech, San Diego, Calif.) Other tags and purification systems are similarly operable.

[0092] It is appreciated that a target protein or protein substructure is optionally not tagged. Purification is optionally achieved by methods known in the art illustratively including ion-exchange chromatography, affinity chromatography using anti-target protein or substructure protein antibodies, precipitation with salt such as ammonium sulfate, streptomycin sulfate, or protamine sulfate, reverse phase chromatography, size exclusion chromatography such as gel exclusion chromatography, HPLC, immobilized metal chelate chromatography, or other methods known in the art. One of skill in the art may select the most appropriate isolation and purification techniques without departing from the scope of this invention.

[0093] A target protein, protein substructure, or fragment thereof is optionally chemically synthesized. Methods of chemical synthesis have produced proteins greater than 600 amino acids in length with or without the inclusion of modifications such as glycosylation and phosphorylation. Methods of chemical protein and peptide synthesis illustratively include solid phase protein chemical synthesis. Illustrative methods of chemical protein synthesis are reviewed by Miranda, L P, Peptide Science, 2000, 55.217-26 and Kochendoerfer G G, Curr Opin Drug Discov Devel. 2001; 4(2):205-14, the contents of which are incorporated herein by reference.

[0094] As discussed above, one or more protein substructures includes a capture sequence. Optionally, all protein substructures include a capture sequence. As such, many aspects a multimeric self-assembling protein structure includes a plurality of capture domains available for association with a target protein. The number of protein substructures that include a capture sequence or the number of bound target proteins to a multimeric self-assembling protein structure relative to the total number of such sites available is a target protein saturation level. A saturation level is optionally 1% or greater, optionally 1.6% or greater, optionally 5% or greater, optionally 10% or greater, optionally 20% or greater, optionally 30% or greater, optionally 40% or greater, optionally 50% or greater, optionally 60% or greater, optionally 70% or greater, optionally 80% or greater, optionally 90% or greater, optionally 99% or greater, optionally 100%.

[0095] For successful solution structure or gathering of biological information using cryo-electron microscopy, it was historically believed that the concentration of salt in the buffer system a target is employed in should be less than 200 millimolar (mM). It was discovered using the presently provided processes and materials that the level of salt could be either raised or lowered depending on the desired level of detail in the solution structure and the target protein being analyzed. As such, some aspects of a provided process include salt in the buffer system at a level of 1 mM to 500 mM, or greater, or any value or range there between. Optionally the level of salt is 1 mM or greater, optionally 10 mM or greater, optionally 50 mM or greater, optionally 100 mM or greater, optionally 200 mM or greater, optionally 300 mM or greater, optionally 400 mM or greater, optionally 500 mM or greater. Optionally, the level of salt is 200 mM to 500 mM, optionally 300 mM to 500 mM.

[0096] Processes as provided herein include subjecting the target complex that includes the target protein associated with a multimeric self-assembling protein structure to analyses by cryo-electron microscopy. The use of cryo-electron microscopy to solve protein structures is known in the art and any suitable device typically employed for analysis of protein, nucleic acid, or other target by cryo-electron microscopy are suitable for use in the processes of this disclosure. Methods of cryo-electron microscopy are optionally described by Bai, et al, Trends in biochemical sciences, 2015; 40(1):49-57, Kimanius, et al, eLife, 2016; 5, Kuhlbrand, eLife, 2014; 3:e03678, McMullan, et al., Methods Enzymol, 2016; 579:1-17, and Scheres, eLife, 2014; 3:e03665.

[0097] Cryo-electron microscopy was unexpectedly found to be produce solution structures or biological information of high resolution using the materials and processes as provided herein when analyzing target proteins of low molecular weight, such as 200 kDa or below, or other molecular weight as provided herein. It is typically considered that valuable information about a target protein can be gathered at a resolution with a value of 20 .ANG. or lower. As such, a process optionally produces a three-dimensional structure of a target protein to a value of resolution of 20 .ANG. or lower, optionally 18 .ANG. or lower, optionally 15 .ANG. or lower, optionally 12 .ANG. or lower, optionally 10 .ANG. or lower, optionally 9 .ANG. or lower, optionally 8 .ANG. or lower, optionally 7 .ANG. or lower, optionally 6 .ANG. or lower, optionally 5 .ANG. or lower, optionally 4 .ANG. or lower, optionally 3 .ANG. or lower, optionally 2 .ANG. or lower, optionally 1 .ANG. or lower.

[0098] The provided processes and materials as described herein streamline the entire process of cryo-electron microscopy and other applications by allowing the decoration of a pre-purified protein "nanocage" with the protein-of-interest that bears a capture tag (e.g., SpyTag, SnoopTag, AviTag, respectively) or in the case of the use of monomeric streptavidin as the capture domain, with any molecule-of-interest that is biotinylated, optionally uniformly biotinylated. Uncaptured molecules-of-interest are simply dialyzed away.

[0099] These protein substructures or self-assembled multimeric structures can easily be used alone or as part of a kit for cryo-electron microscopy applications or immunization applications (as it concentrates antigen). These allow for orthologous capture systems that use covalent or high affinity non-covalent bonds. This can also allow for the capture of proteins with commonly used epitope tags by use of an adapter molecule with the monomeric streptavidin capture domain (which binds to biotin).

EXAMPLES

Example 1: Production of Protein Substructures and Multimers Thereof

[0100] Recodonized sequences that expresses the capture sequence of SEQ ID NO: 7, a linker, and the 13-01 scaffold (SEQ ID NO: 1) (together SEQ ID NOs: 11-15) were each ligated into a modified pET28b+ expression vector, and incorporates a 6xHis epitope tag near its N-terminus. Linking the I3-01 scaffold and the capture sequence is accomplished through either direct binding or through a flexible (4xGGS) or rigid (EAAAK (SEQ ID NO: 10), 9xPro, 3xPPA) protein linker. The recombinant protein was expressed in CodonPlus(DE3) strain of E. coli grown in 1-3 L of LB broth in shaker flasks. To produce the soluble protein, the culture was grown to an OD.sub.600 of 0.6 and protein expression was induced by addition of 0.5 mM IPTG (final concentration) and incubated at 37.degree. C. for 3 hours. The cell pellet was suspended in T500 pH 8.0 Solution (20 mM Tris-Cl pH 8.0@RT, 500 mM NaCl, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol) and lysed by 4 rounds of sonication (Per round, 30 pulses at 60% amplitude and 50% duty cycle (Model 450 Branson Digital Sonifier, Disruptor Horn). The crude extract was spun at 15500.times.g for 10 minutes at 4.degree. C. The supernatant was incubated with 5 ml of Ni-NTA resin (Thermo Scientific, Cat #88223) equilibrated in T500 pH 8.0 Solution on a nutator for 1 hour at 4.degree. C. The resin was washed with 10CV T500 pH 8.0 Solution, and protein was eluted using a linear gradient from 0-100% B over 10CV (Buffer A: T500 pH 8.0 Solution; Buffer B: T500 pH 8.0 Solution+300 mM imidazole). The elution pool was then dialyzed into T100 pH 8.5 Solution (20 mM Tris-CI pH 8.5@RT, 100 mM NaCl, 1 mM DTT, and 10% v/v glycerol). The individual protein substructures self-assembled into a plurality of multimeric nanoages. To further purify the nanocages, anion exchange chromatography was performed using a 20 mL bed volume of Q-Sepharose resin that was equilibrated in T100 pH 8.5 Solution (Buffer A). The column was then washed using 3CV Buffer A, and nanocages were eluted using a linear gradient from 0-100% Buffer B (20 mM Tris-Cl pH 8.5 @RT, 1000 mM NaCl, 1 mM DTT, and 10% v/v glycerol) over 20CV. The elution pool was exhaustively dialyzed into 20 mM Tris pH 8.0 @RT, 100 mM NaCl, 1 mM DTT, and 10% glycerol. Lastly, the purified nanocage was concentrated to 2-5 mg/ml using Amicon Ultra Centrifugal Filters (Fisher Scientific Cat #UFC9-003-08).

Example 2: Target Protein Expression

[0101] Full length PyPABP1 (PY17X_1441700, AA1-835) was ligated into a modified pET28b+ expression vector that may or may not incorporate a GST tag on the N-terminus and a tag and 6xHis purification tag on the C-terminus of the expressed protein, which can be cleaved with thrombin and TEV protease, respectively. The recombinant protein was expressed in the Rosetta2 (DE3) pLysS strain of E. coli grown in 20 L LB broth using a 30 L fermenter. To produce soluble protein, the culture was grown to an OD.sub.600 of 0.6, and protein expression was induced by addition of 0.2 mM IPTG (final concentration) and incubated at 21.degree. C. for 17 hr. The cell pellet was suspended in Low Imidazole Buffer (25 mM Tris-Cl pH 7.5 @RT, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol) and lysed by 10 rounds of sonication (each round consisting of 20 pulses at 30% amplitude and 50% duty cycle (Model 450 Branson Digital Sonifier, Disruptor Horn)). The crude extract was spun at 15500.times.g for 10 minutes at 4.degree. C. The supernatant was incubated with 5 ml of Ni-NTA resin (Thermo Scientific, Cat #88223) equilibrated in Low Imidazole Buffer on a nutator for 1 hour at 4.degree. C. The resin was washed with 4CV Mid Imidazole Buffer (25 mM Tris-Cl pH 7.5 @RT, 500 mM NaCl, 50 mM imidazole, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol), and PyPABP1-SpyTag was then eluted using a linear gradient from 0-100% B over 15CV (Buffer A: 25 mM Tris-CI pH 7.5 @RT, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol; Buffer B: 25 mM Tris-Cl pH 7.5 @RT, 500 mM NaCl, 300 mM imidazole, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol). The pooled elution fractions containing the recombinant protein were dialyzed into 10 mM HEPES pH 6.74 @RT, 100 mM NaCl, 1 mM DTT, 1 mM benzamnidine, and 10% v/v glycerol. Next, PyPABP1-SpyTag was purified further using cation exchange chromatography using a 20 mL bed volume of SP-Sepharose resin that was equilibrated in Buffer A (Buffer A: 10 mM HEPES pH 6.74 @RT, 100 mM NaCl, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol). The column was then washed using 3CV Buffer A then eluted using a linear gradient from 0-50% B (Buffer B: 10 mM HEPES pH 6.74 @RT, 1000 mM NaCl, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol) over 20CV. The elution fractions containing the recombinant protein were pooled and exhaustively dialyzed into 20 mM MES pH 6.0 @RT, 100 mM NaCl, 100 mM MgCl.sub.2, 1 mM DTT, and 10% v/v glycerol. Lastly, the purified protein was concentrated to 10-12 mg/ml using Amicon Ultra Centrifugal Filters (Fisher Scientific Cat #UFC9-003-08). The resulting protein has the primary sequence of the GST tagged PyPABP1-SpyTag is SEQ ID NO: 22 and the non-GST tagged sequence is SEQ ID NO: 26 (GSSMGMIANSTNIMPPSFSTASLYVGDLSEDVTEAVLYEIFNTVGHVLSIRVCRDSVTRK SLGYAYVNYHNLADAERALDTLNYTNIKGQPARLMWSHRDPSLRKSGTGNIFVKNLDK TIDNKALFDTFSMFGNILSCKVATDEFGKSKNYGFVHYEDEESAKEAIEKVNGMQLGSK NVYVGHFIKKSERATNDTKFTNLYVKNFPDTVTEAHLKQLFSPYGEITSMIVKSDNKNR KFCFINYSDADSARNAMENLNGKKITEDGKIDYNYDPKKEETEKPANENSNNNTTTEEN TTTSETPAEKKTPDSEPATNKDATPGEDQTSANGTTTTVTSTTDANPDSKTEETPNDNTA NAGTNASTTEKKDNKKSGENTETPNILYVGPHQSRARRHAILKAKFDTLNTESRNKHPG VNLYIKNLDDSMNDQTKELFEPYGTITSAKVMKDDKDQSKGFGFVCFGTHEFFANKAV TEMHLKIINGKPLYVGLAEKREQRLSRLQQRFRMHPIRHHINNALNAPIQYPNSQTAQLQ FNQNTLNYGRPVITSFNQNNLISWRHQQAAAQQQAAHQQAAAQQQLGFNGGLRGQIN QMRLYTQNNMINHNIGQNKANQQLHHNQQYPIGPNPQHQQTNLNAPAQTNPQQLQGA APVPTNQLLNNNMRNMNSRGNRNLPGINIQSPKQMPLNMVGAKQTNPQQNQPQNQPQ NQPQGQPQNQPQQKSGQSIQQQQQQQQQQTIPQNNNFKFTSQARNRMELPNKNGNKV NNMTPGYNNNTTLTAAALASAPPSMQKQVLGENLFPLVANYIHPTLAGKITGMMLEMD NSELLILLENEDQLKKKIDEALAVLQNAKLEAHIVMVDAYKPTKVENLYFQGVEHHHH HH).

[0102] The sequence expressing 2xAP2 DNA binding domain (PF3D7_0604100, AA177-312) was ligated into a modified pET28b+ expression vector which incorporates a GST purification tag and tag SEQ ID NO: 20 on the N-terminus. To remove the GST purification tag, a thrombin protease site was incorporated in between GST purification tag and SEQ ID NO: 20. The recombinant protein was expressed in CodonPlus(DE3) strain of E. coli grown in 3 L of LB broth in shaker flasks. To produce the soluble protein, the culture was grown to an OD.sub.600 of 0.6, and protein expression was induced by addition of 0.5 mM IPTG (final concentration) and incubated at 23.degree. C. for 18 hrs. The cell pellet was suspended in GST Lysis Buffer (50 mM Tris-Cl pH 8.0 @RT, 150 mM NaCl, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol) and lysed by 4 rounds of sonication (each round consisting of 30 pulses at 60% amplitude and 50% duty cycle (Model 450 Branson Digital Sonifier, Disruptor Horn)). The crude extract was spun at 15500.times.g for 10 minutes at 4.degree. C. The supernatant was incubated with 4 ml of Glutathione Agarose resin (Thermo Scientific, Cat #PI16101) equilibrated in GST Lysis Buffer on a nutator for 1 hour at 4.degree. C. The resin was washed with 10CV GST Lysis Buffer then eluted using 10CV GST Elution Buffer (50 mM Tris-Cl pH 8.0 @RT, 150 mM NaCl, 20 mM reduced glutathione, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol). To remove the GST tag, thrombin was added to the elution pool to a final concentration of 10 units/ml to permit digestion for 18 hours at 4.degree. C. To purify the target protein further, cation exchange chromatography was performed using a 20 mL bed volume of SP-Sepharose resin that was equilibrated in Buffer A (20 mM HEPES pH 7.5 @RT, 100 mM NaCl, 1 mM DTT, and 10% v/v glycerol). The column was then washed using 3CV Buffer A then eluted using a linear gradient from 0-100% Buffer B (20 mM HEPES pH 7.5 @RT, 1000 mM NaCl, 1 mM DTT, and 10% v/v glycerol) over 20CV. Lastly, the purified target protein was concentrated to 2-5 mg/ml using Amicon Ultra Centrifugal Filters (Fisher Scientific Cat #UFC9-003-08). The resulting target protein is SEQ ID NO: 27 (GSHSAHIVMVDAYKPTKAMIGSQEPVILIDKIERCLVVEWYENNIRREQRISYKKYGND KAKLRAKELIEKLKSGITFEQLYPDKGPPIVRVFENVGVYNVSLIRDRIEREWRVEWLEN GVPMKARWSCKKVGNDEAQKRADTFAQSMIKGIFNP).

[0103] The sequence expressing a putative TTP-binding domain (PY17X_0945600, AA1-199) was ligated into a modified pET28b+ expression vector which incorporates a GST tag, 6xHis, and SEQ ID NO: 20 on the N-terminus. To remove the GST tag and 6xHis, a thrombin protease site was incorporated in between 6xHis and the SEQ ID NO: 20 sequences. The recombinant protein was expressed in CodonPlus(DE3) strain of E. coli grown in 8 L of LB broth in shaker flasks. To produce the soluble protein, the culture was grown to an OD.sub.600 of 0.6, and protein expression was induced by addition of 0.5 mM IPTG (final concentration) and incubated at 18.degree. C. for 18 hrs. The cell pellet was suspended in GST Lysis Buffer (50 mM Tris-Cl pH 8.0 @RT, 150 mM NaCl, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol) and lysed by 4 rounds of sonication (each round consisting of 30 pulses at 60% amplitude and 50% duty cycle (Model 450 Branson Digital Sonifier, Disruptor Horn)). The crude extract was spun at 15500.times.g for 10 minutes at 4.degree. C. The supernatant was passed over a 5 ml of Glutathione Agarose resin (Thermo Scientific, Cat #P116101) column that was equilibrated in GST Lysis Buffer. The resin was washed with 10CV GST Lysis Buffer then eluted using 5CV GST Elution Buffer (50 mM Tris-Cl pH 8.0 @RT, 150 mM NaCl, 20 mM reduced glutathione, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol). To remove the GST and 6xHis tags, thrombin was added to the elution pool to a final concentration of 10 units/nil to permit digestion for 18 hours at 4.degree. C. while dialyzing into 20 mM HEPES pH 6.76, 150 mM NaCl, 1 mM DTT, and 10% glycerol. To purify target protein further, cation exchange chromatography was performed using a 20 ml, bed volume of SP-Sepharose resin that was equilibrated in Buffer A (20 mM HEPES pH 6.76 @RT, 75 mM NaCl, 1 mM DTT, and 10% v/v glycerol). The column was then washed using 3CV Buffer A then eluted using a linear gradient from 0-100% Buffer B (20 mM HEPES pH 6.76 @RT, 1000 mM NaCl, 1 mM DTT, and 10% v/v glycerol) over 20CV. The elution pool was adjusted to 20 mM HEPES pH 6.76 @RT, 400 mM NaCl, 1 mM DTT, and 10% v/v glycerol. Lastly, the purified target protein was concentrated to .about.1 mg/ml using Amicon Ultra Centrifugal Filters (Fisher Scientific Cat #UFC9-003-08). The resulting purified target protein had the sequence of SEQ ID NO: 28 (GSHIAHIVMVDAYKPTKHMNNNFNINLQIEDGITNKYEAEVNGYFAKLYTGEITVNTMI DIMKNLSCSPKGSKNNDIYKSMLLILFNECKFFPKYPVEELDITAQLFGKLIKHNLLISYG NTLSVVLKCILEALKKGSDSKVFNFGITALEQFEDSLICYPAFLSSLIPLPTLRQYNPQYIIH CNELLNTLPEQFRTLPYIDASTILKIKHISEISS).

[0104] The sequence expressing UIS12 RNA recognition motifs 1 and 2 (PY17X_0507300, AA246-439) was ligated into a modified pET28b+ expression vector which incorporates a GST tag, 6xHis tag, and SEQ ID NO: 20 on the N-terminus, and a 6xHis tag on the C-terminus. To remove the N-terminal GST and 6xHis tags, a thrombin protease site was incorporated in between 6xHis and the SpyTag sequences. The recombinant protein was expressed in CodonPlus(DE3) strain of E co/i grown in 3 L of LB broth in shaker flasks. To produce the soluble protein, the culture was grown to an OD.sub.600 of 0.6, and protein expression was induced by addition of 0.5 mM IPTG (final concentration) and incubated at 23.degree. C. for 18 hrs. The cell pellet was suspended in Low Imidazole Buffer (25 mM Tris-Cl pH 7.5 @RT, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol) and lysed by 4 rounds of sonication (each round consisting of 30 pulses at 60% amplitude and 50% duty cycle (Model 450 Branson Digital Sonifier, Disruptor Horn)). The crude extract was spun at 15500.times.g for 10 minutes at 4.degree. C. The supernatant was incubated with 5 ml of Ni-NTA resin (Thermo Scientific, Cat #88223) equilibrated in Low Imidazole Buffer on a nutator for 1 hour at 4.degree. C. The resin was washed with 10CV Low Imidazole Buffer, then 4CV Mid Imidazole Buffer (25 mM Tris-Cl pH 7.5 @RT, 500 mM NaCl, 50 mM imidazole, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol), and finally eluted with 6CV of High Imidazole Buffer (25 mM Tris-Cl pH 7.5 @RT, 500 mM NaCl, 300 mM imidazole, 1 mM DTT, 1 mM benzamidine, and 10% v/v glycerol). To remove the N-terminal GST tag and 6xHis, thrombin was added to the elution pool to a final concentration of 10 units/ml to permit digestion for 18 hours at 4.degree. C. while dialyzing into 20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, and 10% v/v glycerol. To purify the target protein further, cation exchange chromatography was performed using a 20 mL bed volume of SP-Sepharose resin that was equilibrated in Buffer A (20 mM HEPES pH 7.5 @RT, 100 mM NaCl, 1 mM DTT, and 10% v/v glycerol). The column was then washed using 3CV Buffer A then eluted using a linear gradient from 0-100% Buffer B (20 mM HEPES pH 7.5 @RT, 1000 mM NaCl, 1 mM DTT, and 10% v/v glycerol) over 20CV. The elution pool was exhaustively dialyzed into 20 mM HEPES pH 7.5 @RT, 400 mM NaCl, 1 mM DTT, and 10% v/v glycerol. Lastly, the purified protein was concentrated to .about.0.5 mg/ml using Amicon Ultra Centrifugal Filters (Fisher Scientific Cat #UFC9-003-08). The resulting target protein has a sequence of SEQ ID NO: 29 (GSHIAHIVMVDAYKPTKHMKNVIITNVFLGNIPPNIIEERLKNVLEIFGYIIHIEYKWSLD KWSYAFIYFIEEKCAINAVNILNQKKFFDNSPNHKLICFIVSKQIPNQNTLHYSKANFSLL KDGPPGANLFLYGIPLKWTELNLIQLVNKYGHVVGLRIPYINNDNDKKQGNRGFGFVSY DNKKSAVEAFEELSKMYIHGKLLKVQLKNGEELENLYFQGVEHHHHHH).

Example 3: Loading Multimeric Self-Assembling Protein Structures with Target Protein

[0105] To determine a desirable molar ratio of multimeric structures to target protein-of-interest, different degrees of saturation of the nanocages were performed by a titration experiment, in which the concentration of multimer is kept constant while the concentration of the target protein-of-interest is varied. Target proteins of PyPABP1, AP2, TTP BD, and UIS12 were tested. The standard buffer condition is 20 mM Tris-Cl pH 8.0 @RT, 100 mM NaCl, 1 mM DTT. The standard molar ratios that are tested are molar concentration ratios of 1:0.2, 1:0.5, 1:1, 1:2, 1:3, 1:4, and 1:5 protein substructure monomer to target protein with a final concentration of protein substructure monomer between 0.2-1 mg/ml. The reactions are performed at room temperature for 2-3 hours depending on the rate of each independent reaction, which can vary depending on the protein-of-interest. The extent of saturation of the multimer nanocages is determined using SDS-PAGE, as binding of a protein-of-interest produces a covalent bond with the scaffold protein, and an easily observable shift in mass is detectable. Variables that affect the stability of loaded cages include NaCl concentration (100-500 mM), the extent of scaffold saturation (50-100%), total protein concentration, and the length of the loading reaction. As illustrated in FIG. 1A, the PyPABP1:nanocage interaction is strong and successful at both 1:1 and 1:2 molar ratios allowing near full saturation of the nanocage with PyPABP1. FIG. 1B illustrates the binding of 2xAP2 to nanocages at various molar ratios where intact bound nanocages are readily observed at all concentrations tested. For 2xAP2, the binding to the nanocage was performed at 500 mM NaCl illustrating successful saturation at relatively high salt concentrations. FIG. 1C illustrates selective binding of target protein TTP to nanocages. When performed at 100 mM NaCl concentration in the reaction buffer near full saturation of the nanocages is observed. As illustrated in FIG. 1D, UIS12 RRM are readily formed. The target bound nanocages were also subjected to a 2 hour incubation at RT in 100 mM NaCl at the various concentrations. As is shown in the right panel of FIG. 1D at about 50% saturation, the interaction between the nanocages and the target protein are stable.

Example 4

[0106] The empty nanocages (no target protein bound, but may have the capture sequence and a linker) formed as in Example 1 are studied by transmission electron microscopy (TEM) or cryo-EM to obtain structural information about the nanocages. For TEM, 3 .mu.L of sample is applied to a carbon-coated 300-mesh grid and stained with neutral 0.3% phosphotungstic acid. The samples are assessed for purity, stability, and concentration with a Tecnai G2 Spirit BioTwin operated at 120 kV. For cryo-EM, 3 .mu.L of sample is applied three times to a 2/1 copper Quantifoil grid and manually botted after the first and second application. After the third application, the quantifoil is blotted for 3 seconds at -10 blot force and plunge frozen in liquid ethane with a Vitribot freezing robot. High-resolution cryo-EM data is collected on a Titan Krios at 300 kV with either the Falcon III or K2 direct electron detector. Micrographs are typically collected at a magnification that results in a pixel size of 1.013 or 1.136 Angstroms per pixel. Micrographs are motion and CTF corrected with MotionCor2 (Zheng, et al, Nature Methods, 2016, submitted. BioArxiv: http://biorxiv.org/content/early/2016/07/04/061960) and GCTF (Zhang, J. Struct. Biol., 2016; 193(1): 1-12), respectively. Particles are then selected, extracted, classified, and refined through RELION/2.1 (Scheres, J. Struct. Biol, 2012; 193(1): 1-12), using the model of the scaffold cage as an input reference model (Hsia, et al., Nature, 2016; 535:136-139). Healpix order must be 5, not the default of 2, during 3D classification for appropriate global alignment of the scaffold to occur.

[0107] The cryo-EM structure of the empty nanocage is illustrated in FIGS. 2A and 2B demonstrating sufficient resolution to observe secondary structure as well as substructure protein interactions. The nanocage of Example 1 with a fused capture sequence of PDB accession number is 4MLS linked to the N-termini of each of the substructure proteins was similarly analyzed by cryo-EM with the results illustrated in FIG. 3. The flexible linker being a 4-mer repeat of GGS was introduced between the capture sequence and the substructure proteins. The reconstruction was solved to a resolution of about 15 .ANG.. In this instance, the flexible linker moves the capture sequence density toward the 5-fold face of the cages.

[0108] Replacing the flexible 4xGGS linker with a rigid 3xPPA linker resulted in the capture domain sequence density outward from the scaffold for excellent association with any desired target protein displaying a suitable tag that can associate with the capture sequence. The results of the cryo-EM are illustrated in FIG. 4.

[0109] The exemplary target protein cytosolic Poly-A Binding Protein (PABP) with a tag complementary to the capture sequence was bound to the nanocage including a flexible 4xGGS linker and the solution structure solved by cryo-EM as above. The resulting 15 .ANG. resolution map reveals non-cage density consistent with additional capture domain and target protein densities.

[0110] Various modifications of the present invention, in addition to those shown and described herein, will be apparent to those skilled in the art of the above description.

[0111] It is appreciated that all reagents used in the manufacture or use of the materials of the present disclosure are obtainable by sources known in the art unless otherwise specifie.

[0112] Patents, publications, and applications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents, publications, and applications are incorporated herein by reference to the same extent as if each individual patent, publication, or application was specifically and individually incorporated herein by reference.

Sequence CWU 1

1

291205PRTArtificial SequenceI3-01 sequence 1Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu Arg Ala1 5 10 15Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala Val Phe Leu Gly 20 25 30Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala Asp Thr 35 40 45Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly Ala Ile Ile Gly 50 55 60Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val Glu Ser65 70 75 80Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile Ser Gln 85 90 95Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met Thr Pro 100 105 110Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr Ile Leu Lys Leu 115 120 125Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met Lys Gly 130 135 140Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn Leu Asp145 150 155 160Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly Val Gly 165 170 175Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala Glu Lys Ala Lys 180 185 190Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His Met 195 200 2052205PRTArtificial SequenceI3-01 sequence EAAAK-v1 2Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu Arg Ala1 5 10 15Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala Val Phe Leu Gly 20 25 30Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala Asp Thr 35 40 45Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly Ala Ile Ile Gly 50 55 60Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val Glu Ser65 70 75 80Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile Ser Gln 85 90 95Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met Thr Pro 100 105 110Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr Ile Leu Lys Leu 115 120 125Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met Lys Gly 130 135 140Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn Leu Asp145 150 155 160Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly Val Gly 165 170 175Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala Glu Lys Ala Lys 180 185 190Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His Met 195 200 2053201PRTArtificial SequenceI3-01 sequence EAAAK-v2, 9x-Pro, and 3xPPA 3Phe Lys Lys His Lys Ile Val Ala Val Leu Arg Ala Asn Ser Val Glu1 5 10 15Glu Ala Lys Lys Lys Ala Leu Ala Val Phe Leu Gly Gly Val His Leu 20 25 30Ile Glu Ile Thr Phe Thr Val Pro Asp Ala Asp Thr Val Ile Lys Glu 35 40 45Leu Ser Phe Leu Lys Glu Met Gly Ala Ile Ile Gly Ala Gly Thr Val 50 55 60Thr Ser Val Glu Gln Cys Arg Lys Ala Val Glu Ser Gly Ala Glu Phe65 70 75 80Ile Val Ser Pro His Leu Asp Glu Glu Ile Ser Gln Phe Cys Lys Glu 85 90 95Lys Gly Val Phe Tyr Met Pro Gly Val Met Thr Pro Thr Glu Leu Val 100 105 110Lys Ala Met Lys Leu Gly His Thr Ile Leu Lys Leu Phe Pro Gly Glu 115 120 125Val Val Gly Pro Gln Phe Val Lys Ala Met Lys Gly Pro Phe Pro Asn 130 135 140Val Lys Phe Val Pro Thr Gly Gly Val Asn Leu Asp Asn Val Cys Glu145 150 155 160Trp Phe Lys Ala Gly Val Leu Ala Val Gly Val Gly Ser Ala Leu Val 165 170 175Lys Gly Thr Pro Val Glu Val Ala Glu Lys Ala Lys Ala Phe Val Glu 180 185 190Lys Ile Arg Gly Cys Thr Glu His Met 195 2004207PRTArtificial SequenceI3-01 sequence 4Met Lys Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu1 5 10 15Arg Ala Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala Val Phe 20 25 30Leu Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala 35 40 45Asp Thr Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly Ala Ile 50 55 60Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val65 70 75 80Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile 85 90 95Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met 100 105 110Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr Ile Leu 115 120 125Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met 130 135 140Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn145 150 155 160Leu Asp Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly 165 170 175Val Gly Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala Glu Lys 180 185 190Ala Lys Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His Met 195 200 2055206PRTArtificial SequenceI3-03 sequence EAAAK-v1 5Ser Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu Arg1 5 10 15Ala Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala Val Phe Leu 20 25 30Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala Asp 35 40 45Thr Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly Ala Ile Ile 50 55 60Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val Glu65 70 75 80Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile Ser 85 90 95Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met Thr 100 105 110Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr Ile Leu Lys 115 120 125Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met Lys 130 135 140Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn Leu145 150 155 160Asp Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly Val 165 170 175Gly Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala Glu Lys Ala 180 185 190Lys Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His Met 195 200 2056204PRTArtificial SequenceI3-03 sequence EAAAK-v2, 9x-Pro, and 3xPPA 6Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu Arg Ala Asn1 5 10 15Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala Val Phe Leu Gly Gly 20 25 30Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala Asp Thr Val 35 40 45Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly Ala Ile Ile Gly Ala 50 55 60Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val Glu Ser Gly65 70 75 80Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile Ser Gln Phe 85 90 95Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met Thr Pro Thr 100 105 110Glu Leu Val Lys Ala Met Lys Leu Gly His Thr Ile Leu Lys Leu Phe 115 120 125Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met Lys Gly Pro 130 135 140Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn Leu Asp Asn145 150 155 160Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly Val Gly Ser 165 170 175Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala Glu Lys Ala Lys Ala 180 185 190Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His Met 195 200798PRTArtificial SequenceSpycatcher Sequence 7Gly Ser Gly Asp Ser Ala Thr His Ile Lys Phe Ser Lys Arg Asp Glu1 5 10 15Asp Gly Lys Glu Leu Ala Gly Ala Thr Met Glu Leu Arg Asp Ser Ser 20 25 30Gly Lys Thr Ile Ser Thr Trp Ile Ser Asp Gly Gln Val Lys Asp Phe 35 40 45Tyr Leu Tyr Pro Gly Lys Tyr Thr Phe Val Glu Thr Ala Ala Pro Asp 50 55 60Gly Tyr Glu Val Ala Thr Ala Ile Thr Phe Thr Val Asn Glu Gln Gly65 70 75 80Gln Val Thr Val Asn Gly Lys Ala Thr Lys Gly Asp Ala His Ile Gly 85 90 95Val Asp8108PRTArtificial SequenceSpycatcher Sequence with purification tag 8Met Gly Ser Ser His His His His His His Gly Ser Gly Asp Ser Ala1 5 10 15Thr His Ile Lys Phe Ser Lys Arg Asp Glu Asp Gly Lys Glu Leu Ala 20 25 30Gly Ala Thr Met Glu Leu Arg Asp Ser Ser Gly Lys Thr Ile Ser Thr 35 40 45Trp Ile Ser Asp Gly Gln Val Lys Asp Phe Tyr Leu Tyr Pro Gly Lys 50 55 60Tyr Thr Phe Val Glu Thr Ala Ala Pro Asp Gly Tyr Glu Val Ala Thr65 70 75 80Ala Ile Thr Phe Thr Val Asn Glu Gln Gly Gln Val Thr Val Asn Gly 85 90 95Lys Ala Thr Lys Gly Asp Ala His Ile Gly Val Asp 100 1059113PRTArtificial SequenceSnoopCatcher Sequence 9Met Lys Pro Leu Arg Gly Ala Val Phe Ser Leu Gln Lys Gln His Pro1 5 10 15Asp Tyr Pro Asp Ile Tyr Gly Ala Ile Asp Gln Asn Gly Thr Tyr Gln 20 25 30Asn Val Arg Thr Gly Glu Asp Gly Lys Leu Thr Phe Lys Asn Leu Ser 35 40 45Asp Gly Lys Tyr Arg Leu Phe Glu Asn Ser Glu Pro Ala Gly Tyr Lys 50 55 60Pro Val Gln Asn Lys Pro Ile Val Ala Phe Gln Ile Val Asn Gly Glu65 70 75 80Val Arg Asp Val Thr Ser Ile Val Pro Gln Asp Ile Pro Ala Thr Tyr 85 90 95Glu Phe Thr Asn Gly Lys His Tyr Ile Thr Asn Glu Pro Ile Pro Pro 100 105 110Lys105PRTArtificial SequenceSynthetic sequence 10Glu Ala Ala Ala Lys1 511333PRTArtificial SequenceSpyCage(4xGGS) 11Met Gly Ser Ser His His His His His His Gly Ser Gly Asp Ser Ala1 5 10 15Thr His Ile Lys Phe Ser Lys Arg Asp Glu Asp Gly Lys Glu Leu Ala 20 25 30Gly Ala Thr Met Glu Leu Arg Asp Ser Ser Gly Lys Thr Ile Ser Thr 35 40 45Trp Ile Ser Asp Gly Gln Val Lys Asp Phe Tyr Leu Tyr Pro Gly Lys 50 55 60Tyr Thr Phe Val Glu Thr Ala Ala Pro Asp Gly Tyr Glu Val Ala Thr65 70 75 80Ala Ile Thr Phe Thr Val Asn Glu Gln Gly Gln Val Thr Val Asn Gly 85 90 95Lys Ala Thr Lys Gly Asp Ala His Ile Gly Val Asp His His His His 100 105 110His His Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Met Lys 115 120 125Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu Arg Ala 130 135 140Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala Val Phe Leu Gly145 150 155 160Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala Asp Thr 165 170 175Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly Ala Ile Ile Gly 180 185 190Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val Glu Ser 195 200 205Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile Ser Gln 210 215 220Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met Thr Pro225 230 235 240Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr Ile Leu Lys Leu 245 250 255Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met Lys Gly 260 265 270Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn Leu Asp 275 280 285Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly Val Gly 290 295 300Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala Glu Lys Ala Lys305 310 315 320Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His Met 325 33012340PRTArtificial SequenceSpyCage(EAAAK-v1) 12Met Gly Ser Ser His His His His His His Gly Ser Gly Asp Ser Ala1 5 10 15Thr His Ile Lys Phe Ser Lys Arg Asp Glu Asp Gly Lys Glu Leu Ala 20 25 30Gly Ala Thr Met Glu Leu Arg Asp Ser Ser Gly Lys Thr Ile Ser Thr 35 40 45Trp Ile Ser Asp Gly Gln Val Lys Asp Phe Tyr Leu Tyr Pro Gly Lys 50 55 60Tyr Thr Phe Val Glu Thr Ala Ala Pro Asp Gly Tyr Glu Val Ala Thr65 70 75 80Ala Ile Thr Phe Thr Val Asn Glu Gln Gly Gln Val Thr Val Asn Gly 85 90 95Lys Ala Thr Lys Gly Asp Ala His Ile Gly Val Asp Glu Ala Ala Ala 100 105 110Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys 115 120 125Glu Ala Ala Ala Lys Ala Ser Met Glu Glu Leu Phe Lys Lys His Lys 130 135 140Ile Val Ala Val Leu Arg Ala Asn Ser Val Glu Glu Ala Lys Lys Lys145 150 155 160Ala Leu Ala Val Phe Leu Gly Gly Val His Leu Ile Glu Ile Thr Phe 165 170 175Thr Val Pro Asp Ala Asp Thr Val Ile Lys Glu Leu Ser Phe Leu Lys 180 185 190Glu Met Gly Ala Ile Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln 195 200 205Cys Arg Lys Ala Val Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His 210 215 220Leu Asp Glu Glu Ile Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr225 230 235 240Met Pro Gly Val Met Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu 245 250 255Gly His Thr Ile Leu Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln 260 265 270Phe Val Lys Ala Met Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro 275 280 285Thr Gly Gly Val Asn Leu Asp Asn Val Cys Glu Trp Phe Lys Ala Gly 290 295 300Val Leu Ala Val Gly Val Gly Ser Ala Leu Val Lys Gly Thr Pro Val305 310 315 320Glu Val Ala Glu Lys Ala Lys Ala Phe Val Glu Lys Ile Arg Gly Cys 325 330 335Thr Glu His Met 34013337PRTArtificial SequenceSpyCage(EAAAK-v2) 13Met Gly Ser Ser His His His His His His Gly Ser Gly Asp Ser Ala1 5 10 15Thr His Ile Lys Phe Ser Lys Arg Asp Glu Asp Gly Lys Glu Leu Ala 20 25 30Gly Ala Thr Met Glu Leu Arg Asp Ser Ser Gly Lys Thr Ile Ser Thr 35 40 45Trp Ile Ser Asp Gly Gln Val Lys Asp Phe Tyr Leu Tyr Pro Gly Lys 50 55 60Tyr Thr Phe Val Glu Thr Ala Ala Pro Asp Gly Tyr Glu Val Ala Thr65 70 75 80Ala Ile Thr Phe Thr Val Asn Glu Gln Gly Gln Val Thr Val Asn Gly 85 90 95Lys Ala Thr Lys Gly Asp Ala His Ile Gly Val Asp Glu Ala Ala Ala 100 105 110Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys 115 120 125Glu Ala Ala Ala Lys Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala 130 135 140Val Leu Arg Ala Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala145 150

155 160Val Phe Leu Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro 165 170 175Asp Ala Asp Thr Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly 180 185 190Ala Ile Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys 195 200 205Ala Val Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu 210 215 220Glu Ile Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly225 230 235 240Val Met Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr 245 250 255Ile Leu Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys 260 265 270Ala Met Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly 275 280 285Val Asn Leu Asp Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala 290 295 300Val Gly Val Gly Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala305 310 315 320Glu Lys Ala Lys Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His 325 330 335Met14321PRTArtificial SequenceSpyCage(9xPro) 14Met Gly Ser Ser His His His His His His Gly Ser Gly Asp Ser Ala1 5 10 15Thr His Ile Lys Phe Ser Lys Arg Asp Glu Asp Gly Lys Glu Leu Ala 20 25 30Gly Ala Thr Met Glu Leu Arg Asp Ser Ser Gly Lys Thr Ile Ser Thr 35 40 45Trp Ile Ser Asp Gly Gln Val Lys Asp Phe Tyr Leu Tyr Pro Gly Lys 50 55 60Tyr Thr Phe Val Glu Thr Ala Ala Pro Asp Gly Tyr Glu Val Ala Thr65 70 75 80Ala Ile Thr Phe Thr Val Asn Glu Gln Gly Gln Val Thr Val Asn Gly 85 90 95Lys Ala Thr Lys Gly Asp Ala His Ile Gly Val Asp Pro Pro Pro Pro 100 105 110Pro Pro Pro Pro Pro Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala 115 120 125Val Leu Arg Ala Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala 130 135 140Val Phe Leu Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro145 150 155 160Asp Ala Asp Thr Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly 165 170 175Ala Ile Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys 180 185 190Ala Val Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu 195 200 205Glu Ile Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly 210 215 220Val Met Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr225 230 235 240Ile Leu Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys 245 250 255Ala Met Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly 260 265 270Val Asn Leu Asp Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala 275 280 285Val Gly Val Gly Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala 290 295 300Glu Lys Ala Lys Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His305 310 315 320Met15321PRTArtificial SequenceSpyCage(3xPPA) 15Met Gly Ser Ser His His His His His His Gly Ser Gly Asp Ser Ala1 5 10 15Thr His Ile Lys Phe Ser Lys Arg Asp Glu Asp Gly Lys Glu Leu Ala 20 25 30Gly Ala Thr Met Glu Leu Arg Asp Ser Ser Gly Lys Thr Ile Ser Thr 35 40 45Trp Ile Ser Asp Gly Gln Val Lys Asp Phe Tyr Leu Tyr Pro Gly Lys 50 55 60Tyr Thr Phe Val Glu Thr Ala Ala Pro Asp Gly Tyr Glu Val Ala Thr65 70 75 80Ala Ile Thr Phe Thr Val Asn Glu Gln Gly Gln Val Thr Val Asn Gly 85 90 95Lys Ala Thr Lys Gly Asp Ala His Ile Gly Val Asp Pro Pro Ala Pro 100 105 110Pro Ala Pro Pro Ala Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala 115 120 125Val Leu Arg Ala Asn Ser Val Glu Glu Ala Lys Lys Lys Ala Leu Ala 130 135 140Val Phe Leu Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro145 150 155 160Asp Ala Asp Thr Val Ile Lys Glu Leu Ser Phe Leu Lys Glu Met Gly 165 170 175Ala Ile Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys 180 185 190Ala Val Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu 195 200 205Glu Ile Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly 210 215 220Val Met Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr225 230 235 240Ile Leu Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys 245 250 255Ala Met Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly 260 265 270Val Asn Leu Asp Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala 275 280 285Val Gly Val Gly Ser Ala Leu Val Lys Gly Thr Pro Val Glu Val Ala 290 295 300Glu Lys Ala Lys Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu His305 310 315 320Met161072PRTArtificial Sequencecytosolic Poly-A Binding Protein (PABP) 16Met Thr Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val1 5 10 15Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu 20 25 30His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe 35 40 45Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp 50 55 60Val Lys Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys65 70 75 80His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met 85 90 95Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala 100 105 110Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu 115 120 125Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr 130 135 140Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala145 150 155 160Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro 165 170 175Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp 180 185 190Lys Tyr Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp 195 200 205Gln Ala Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val 210 215 220Pro Arg Gly Ser Ser Met Gly Met Ile Ala Asn Ser Thr Asn Ile Met225 230 235 240Pro Pro Ser Phe Ser Thr Ala Ser Leu Tyr Val Gly Asp Leu Ser Glu 245 250 255Asp Val Thr Glu Ala Val Leu Tyr Glu Ile Phe Asn Thr Val Gly His 260 265 270Val Leu Ser Ile Arg Val Cys Arg Asp Ser Val Thr Arg Lys Ser Leu 275 280 285Gly Tyr Ala Tyr Val Asn Tyr His Asn Leu Ala Asp Ala Glu Arg Ala 290 295 300Leu Asp Thr Leu Asn Tyr Thr Asn Ile Lys Gly Gln Pro Ala Arg Leu305 310 315 320Met Trp Ser His Arg Asp Pro Ser Leu Arg Lys Ser Gly Thr Gly Asn 325 330 335Ile Phe Val Lys Asn Leu Asp Lys Thr Ile Asp Asn Lys Ala Leu Phe 340 345 350Asp Thr Phe Ser Met Phe Gly Asn Ile Leu Ser Cys Lys Val Ala Thr 355 360 365Asp Glu Phe Gly Lys Ser Lys Asn Tyr Gly Phe Val His Tyr Glu Asp 370 375 380Glu Glu Ser Ala Lys Glu Ala Ile Glu Lys Val Asn Gly Met Gln Leu385 390 395 400Gly Ser Lys Asn Val Tyr Val Gly His Phe Ile Lys Lys Ser Glu Arg 405 410 415Ala Thr Asn Asp Thr Lys Phe Thr Asn Leu Tyr Val Lys Asn Phe Pro 420 425 430Asp Thr Val Thr Glu Ala His Leu Lys Gln Leu Phe Ser Pro Tyr Gly 435 440 445Glu Ile Thr Ser Met Ile Val Lys Ser Asp Asn Lys Asn Arg Lys Phe 450 455 460Cys Phe Ile Asn Tyr Ser Asp Ala Asp Ser Ala Arg Asn Ala Met Glu465 470 475 480Asn Leu Asn Gly Lys Lys Ile Thr Glu Asp Gly Lys Ile Asp Tyr Asn 485 490 495Tyr Asp Pro Lys Lys Glu Glu Thr Glu Lys Pro Ala Asn Glu Asn Ser 500 505 510Asn Asn Asn Thr Thr Thr Glu Glu Asn Thr Thr Thr Ser Glu Thr Pro 515 520 525Ala Glu Lys Lys Thr Pro Asp Ser Glu Pro Ala Thr Asn Lys Asp Ala 530 535 540Thr Pro Gly Glu Asp Gln Thr Ser Ala Asn Gly Thr Thr Thr Thr Val545 550 555 560Thr Ser Thr Thr Asp Ala Asn Pro Asp Ser Lys Thr Glu Glu Thr Pro 565 570 575Asn Asp Asn Thr Ala Asn Ala Gly Thr Asn Ala Ser Thr Thr Glu Lys 580 585 590Lys Asp Asn Lys Lys Ser Gly Glu Asn Thr Glu Thr Pro Asn Ile Leu 595 600 605Tyr Val Gly Pro His Gln Ser Arg Ala Arg Arg His Ala Ile Leu Lys 610 615 620Ala Lys Phe Asp Thr Leu Asn Thr Glu Ser Arg Asn Lys His Pro Gly625 630 635 640Val Asn Leu Tyr Ile Lys Asn Leu Asp Asp Ser Met Asn Asp Gln Thr 645 650 655Leu Lys Glu Leu Phe Glu Pro Tyr Gly Thr Ile Thr Ser Ala Lys Val 660 665 670Met Lys Asp Asp Lys Asp Gln Ser Lys Gly Phe Gly Phe Val Cys Phe 675 680 685Gly Thr His Glu Glu Ala Asn Lys Ala Val Thr Glu Met His Leu Lys 690 695 700Ile Ile Asn Gly Lys Pro Leu Tyr Val Gly Leu Ala Glu Lys Arg Glu705 710 715 720Gln Arg Leu Ser Arg Leu Gln Gln Arg Phe Arg Met His Pro Ile Arg 725 730 735His His Ile Asn Asn Ala Leu Asn Ala Pro Ile Gln Tyr Pro Asn Ser 740 745 750Gln Thr Ala Gln Leu Gln Phe Asn Gln Asn Thr Leu Asn Tyr Gly Arg 755 760 765Pro Val Ile Thr Ser Phe Asn Gln Asn Asn Leu Ile Ser Trp Arg His 770 775 780Gln Gln Ala Ala Ala Gln Gln Gln Ala Ala His Gln Gln Ala Ala Ala785 790 795 800Gln Gln Gln Leu Gly Phe Asn Gly Gly Leu Arg Gly Gln Ile Asn Gln 805 810 815Met Arg Leu Tyr Thr Gln Asn Asn Met Ile Asn His Asn Ile Gly Gln 820 825 830Asn Lys Ala Asn Gln Gln Leu His His Asn Gln Gln Tyr Pro Ile Gly 835 840 845Pro Asn Pro Gln His Gln Gln Thr Asn Leu Asn Ala Pro Ala Gln Thr 850 855 860Asn Pro Gln Gln Leu Gln Gly Ala Ala Pro Val Pro Thr Asn Gln Leu865 870 875 880Leu Asn Asn Asn Met Arg Asn Met Asn Ser Arg Gly Asn Arg Asn Leu 885 890 895Pro Gly Ile Asn Ile Gln Ser Pro Lys Gln Met Pro Leu Asn Met Val 900 905 910Gly Ala Lys Gln Thr Asn Pro Gln Gln Asn Gln Pro Gln Asn Gln Pro 915 920 925Gln Asn Gln Pro Gln Gly Gln Pro Gln Asn Gln Pro Gln Gln Lys Ser 930 935 940Gly Gln Ser Ile Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Thr Ile945 950 955 960Pro Gln Asn Asn Asn Phe Lys Phe Thr Ser Gln Ala Arg Asn Arg Met 965 970 975Glu Leu Pro Asn Lys Asn Gly Asn Lys Val Asn Asn Met Thr Pro Gly 980 985 990Tyr Asn Asn Asn Thr Thr Leu Thr Ala Ala Ala Leu Ala Ser Ala Pro 995 1000 1005Pro Ser Met Gln Lys Gln Val Leu Gly Glu Asn Leu Phe Pro Leu 1010 1015 1020Val Ala Asn Tyr His Pro Thr Leu Ala Gly Lys Ile Thr Gly Met 1025 1030 1035Met Leu Glu Met Asp Asn Ser Glu Leu Leu Ile Leu Leu Glu Asn 1040 1045 1050Glu Asp Gln Leu Lys Lys Lys Ile Asp Glu Ala Leu Ala Val Leu 1055 1060 1065Gln Asn Ala Lys 107017135PRTArtificial SequenceDNA-binding protein of the ApiAP2 specific transcription factor family 17Gly Ser Gln Glu Pro Val Ile Leu Ile Asp Lys Ile Glu Arg Cys Leu1 5 10 15Val Val Glu Trp Tyr Glu Asn Asn Ile Arg Arg Glu Gln Arg Ile Ser 20 25 30Tyr Lys Lys Tyr Gly Asn Asp Lys Ala Lys Leu Arg Ala Lys Glu Leu 35 40 45Ile Glu Lys Leu Lys Ser Gly Ile Thr Phe Glu Gln Leu Tyr Pro Asp 50 55 60Lys Gly Pro Pro Ile Val Arg Val Phe Glu Asn Val Gly Val Tyr Asn65 70 75 80Val Ser Leu Ile Arg Asp Arg Ile Glu Arg Glu Trp Arg Val Glu Trp 85 90 95Leu Glu Asn Gly Val Pro Met Lys Ala Arg Trp Ser Cys Lys Lys Val 100 105 110Gly Asn Asp Glu Ala Gln Lys Arg Ala Asp Thr Phe Ala Gln Ser Met 115 120 125Ile Lys Gly Ile Phe Asn Pro 130 13518198PRTArtificial Sequencebinding domain of tristetraprolin (TTP) of a NOT family protein 18Asn Asn Asn Phe Asn Ile Asn Leu Gln Ile Glu Asp Gly Ile Thr Asn1 5 10 15Lys Tyr Glu Ala Glu Val Asn Gly Tyr Phe Ala Lys Leu Tyr Thr Gly 20 25 30Glu Ile Thr Val Asn Thr Met Ile Asp Ile Met Lys Asn Leu Ser Cys 35 40 45Ser Pro Lys Gly Ser Lys Asn Asn Asp Ile Tyr Lys Ser Met Leu Leu 50 55 60Ile Leu Phe Asn Glu Cys Lys Phe Phe Pro Lys Tyr Pro Val Glu Glu65 70 75 80Leu Asp Ile Thr Ala Gln Leu Phe Gly Lys Leu Ile Lys His Asn Leu 85 90 95Leu Ile Ser Tyr Gly Asn Thr Leu Ser Val Val Leu Lys Cys Ile Leu 100 105 110Glu Ala Leu Lys Lys Gly Ser Asp Ser Lys Val Phe Asn Phe Gly Ile 115 120 125Thr Ala Leu Glu Gln Phe Glu Asp Ser Leu Ile Cys Tyr Pro Ala Phe 130 135 140Leu Ser Ser Leu Ile Pro Leu Pro Thr Leu Arg Gln Tyr Asn Pro Gln145 150 155 160Tyr Ile Ile His Cys Asn Glu Leu Leu Asn Thr Leu Pro Glu Gln Phe 165 170 175Arg Thr Leu Pro Tyr Ile Asp Ala Ser Thr Ile Leu Lys Ile Lys His 180 185 190Ile Ser Glu Ile Ser Ser 19519194PRTArtificial SequenceRNA-recognition motif of the Upregulated in Infectious Sporozoites 12 (UIS12) protein 19Lys Asn Val Ile Ile Thr Asn Val Phe Leu Gly Asn Ile Pro Pro Asn1 5 10 15Ile Thr Glu Glu Arg Leu Lys Asn Val Leu Glu Ile Phe Gly Tyr Ile 20 25 30Ile His Ile Glu Tyr Lys Trp Ser Leu Asp Lys Trp Ser Tyr Ala Phe 35 40 45Ile Tyr Phe Ile Glu Glu Lys Cys Ala Ile Asn Ala Val Asn Ile Leu 50 55 60Asn Gln Lys Lys Phe Phe Asp Asn Ser Pro Asn His Lys Leu Ile Cys65 70 75 80Phe Ile Val Ser Lys Gln Ile Pro Asn Gln Asn Thr Leu His Tyr Ser 85 90 95Lys Ala Asn Phe Ser Leu Leu Lys Asp Gly Pro Pro Gly Ala Asn Leu 100 105 110Phe Leu Tyr Gly Ile Pro Leu Lys Trp Thr Glu Leu Asn Leu Ile Gln 115 120 125Leu Val Asn Lys Tyr Gly His Val Val Gly Leu Arg Ile Pro Tyr Ile 130 135 140Asn Asn Asp Asn Asp Lys Lys Gln Gly Asn Arg Gly Phe Gly Phe Val145 150 155 160Ser Tyr Asp Asn Lys Lys Ser Ala Val Glu Ala Phe Glu Glu Leu Ser 165 170

175Lys Met Tyr Ile His Gly Lys Leu Leu Lys Val Gln Leu Lys Asn Gly 180 185 190Glu Glu2013PRTArtificial SequenceSpytag sequence 20Ala His Ile Val Met Val Asp Ala Tyr Lys Pro Thr Lys1 5 102113PRTArtificial SequenceSnoopTag 21Lys Leu Gly Asp Ile Glu Phe Ile Lys Val Asn Lys Gly1 5 10221103PRTArtificial SequencePyPABP1-SpyTag 22Met Thr Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val1 5 10 15Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu 20 25 30His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe 35 40 45Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp 50 55 60Val Lys Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys65 70 75 80His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met 85 90 95Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala 100 105 110Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu 115 120 125Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr 130 135 140Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala145 150 155 160Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro 165 170 175Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp 180 185 190Lys Tyr Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp 195 200 205Gln Ala Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val 210 215 220Pro Arg Gly Ser Ser Met Gly Met Ile Ala Asn Ser Thr Asn Ile Met225 230 235 240Pro Pro Ser Phe Ser Thr Ala Ser Leu Tyr Val Gly Asp Leu Ser Glu 245 250 255Asp Val Thr Glu Ala Val Leu Tyr Glu Ile Phe Asn Thr Val Gly His 260 265 270Val Leu Ser Ile Arg Val Cys Arg Asp Ser Val Thr Arg Lys Ser Leu 275 280 285Gly Tyr Ala Tyr Val Asn Tyr His Asn Leu Ala Asp Ala Glu Arg Ala 290 295 300Leu Asp Thr Leu Asn Tyr Thr Asn Ile Lys Gly Gln Pro Ala Arg Leu305 310 315 320Met Trp Ser His Arg Asp Pro Ser Leu Arg Lys Ser Gly Thr Gly Asn 325 330 335Ile Phe Val Lys Asn Leu Asp Lys Thr Ile Asp Asn Lys Ala Leu Phe 340 345 350Asp Thr Phe Ser Met Phe Gly Asn Ile Leu Ser Cys Lys Val Ala Thr 355 360 365Asp Glu Phe Gly Lys Ser Lys Asn Tyr Gly Phe Val His Tyr Glu Asp 370 375 380Glu Glu Ser Ala Lys Glu Ala Ile Glu Lys Val Asn Gly Met Gln Leu385 390 395 400Gly Ser Lys Asn Val Tyr Val Gly His Phe Ile Lys Lys Ser Glu Arg 405 410 415Ala Thr Asn Asp Thr Lys Phe Thr Asn Leu Tyr Val Lys Asn Phe Pro 420 425 430Asp Thr Val Thr Glu Ala His Leu Lys Gln Leu Phe Ser Pro Tyr Gly 435 440 445Glu Ile Thr Ser Met Ile Val Lys Ser Asp Asn Lys Asn Arg Lys Phe 450 455 460Cys Phe Ile Asn Tyr Ser Asp Ala Asp Ser Ala Arg Asn Ala Met Glu465 470 475 480Asn Leu Asn Gly Lys Lys Ile Thr Glu Asp Gly Lys Ile Asp Tyr Asn 485 490 495Tyr Asp Pro Lys Lys Glu Glu Thr Glu Lys Pro Ala Asn Glu Asn Ser 500 505 510Asn Asn Asn Thr Thr Thr Glu Glu Asn Thr Thr Thr Ser Glu Thr Pro 515 520 525Ala Glu Lys Lys Thr Pro Asp Ser Glu Pro Ala Thr Asn Lys Asp Ala 530 535 540Thr Pro Gly Glu Asp Gln Thr Ser Ala Asn Gly Thr Thr Thr Thr Val545 550 555 560Thr Ser Thr Thr Asp Ala Asn Pro Asp Ser Lys Thr Glu Glu Thr Pro 565 570 575Asn Asp Asn Thr Ala Asn Ala Gly Thr Asn Ala Ser Thr Thr Glu Lys 580 585 590Lys Asp Asn Lys Lys Ser Gly Glu Asn Thr Glu Thr Pro Asn Ile Leu 595 600 605Tyr Val Gly Pro His Gln Ser Arg Ala Arg Arg His Ala Ile Leu Lys 610 615 620Ala Lys Phe Asp Thr Leu Asn Thr Glu Ser Arg Asn Lys His Pro Gly625 630 635 640Val Asn Leu Tyr Ile Lys Asn Leu Asp Asp Ser Met Asn Asp Gln Thr 645 650 655Leu Lys Glu Leu Phe Glu Pro Tyr Gly Thr Ile Thr Ser Ala Lys Val 660 665 670Met Lys Asp Asp Lys Asp Gln Ser Lys Gly Phe Gly Phe Val Cys Phe 675 680 685Gly Thr His Glu Glu Ala Asn Lys Ala Val Thr Glu Met His Leu Lys 690 695 700Ile Ile Asn Gly Lys Pro Leu Tyr Val Gly Leu Ala Glu Lys Arg Glu705 710 715 720Gln Arg Leu Ser Arg Leu Gln Gln Arg Phe Arg Met His Pro Ile Arg 725 730 735His His Ile Asn Asn Ala Leu Asn Ala Pro Ile Gln Tyr Pro Asn Ser 740 745 750Gln Thr Ala Gln Leu Gln Phe Asn Gln Asn Thr Leu Asn Tyr Gly Arg 755 760 765Pro Val Ile Thr Ser Phe Asn Gln Asn Asn Leu Ile Ser Trp Arg His 770 775 780Gln Gln Ala Ala Ala Gln Gln Gln Ala Ala His Gln Gln Ala Ala Ala785 790 795 800Gln Gln Gln Leu Gly Phe Asn Gly Gly Leu Arg Gly Gln Ile Asn Gln 805 810 815Met Arg Leu Tyr Thr Gln Asn Asn Met Ile Asn His Asn Ile Gly Gln 820 825 830Asn Lys Ala Asn Gln Gln Leu His His Asn Gln Gln Tyr Pro Ile Gly 835 840 845Pro Asn Pro Gln His Gln Gln Thr Asn Leu Asn Ala Pro Ala Gln Thr 850 855 860Asn Pro Gln Gln Leu Gln Gly Ala Ala Pro Val Pro Thr Asn Gln Leu865 870 875 880Leu Asn Asn Asn Met Arg Asn Met Asn Ser Arg Gly Asn Arg Asn Leu 885 890 895Pro Gly Ile Asn Ile Gln Ser Pro Lys Gln Met Pro Leu Asn Met Val 900 905 910Gly Ala Lys Gln Thr Asn Pro Gln Gln Asn Gln Pro Gln Asn Gln Pro 915 920 925Gln Asn Gln Pro Gln Gly Gln Pro Gln Asn Gln Pro Gln Gln Lys Ser 930 935 940Gly Gln Ser Ile Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Thr Ile945 950 955 960Pro Gln Asn Asn Asn Phe Lys Phe Thr Ser Gln Ala Arg Asn Arg Met 965 970 975Glu Leu Pro Asn Lys Asn Gly Asn Lys Val Asn Asn Met Thr Pro Gly 980 985 990Tyr Asn Asn Asn Thr Thr Leu Thr Ala Ala Ala Leu Ala Ser Ala Pro 995 1000 1005Pro Ser Met Gln Lys Gln Val Leu Gly Glu Asn Leu Phe Pro Leu 1010 1015 1020Val Ala Asn Tyr His Pro Thr Leu Ala Gly Lys Ile Thr Gly Met 1025 1030 1035Met Leu Glu Met Asp Asn Ser Glu Leu Leu Ile Leu Leu Glu Asn 1040 1045 1050Glu Asp Gln Leu Lys Lys Lys Ile Asp Glu Ala Leu Ala Val Leu 1055 1060 1065Gln Asn Ala Lys Leu Glu Ala His Ile Val Met Val Asp Ala Tyr 1070 1075 1080Lys Pro Thr Lys Val Glu Asn Leu Tyr Phe Gln Gly Val Glu His 1085 1090 1095His His His His His 110023379PRTArtificial SequenceSpyTag-2xAP2 23Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro1 5 10 15Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 20 25 30Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 35 40 45Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 50 55 60Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn65 70 75 80Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu 85 90 95Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 100 105 110Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 115 120 125Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 130 135 140Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp145 150 155 160Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 165 170 175Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 180 185 190Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 195 200 205Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg 210 215 220Gly Ser His Ser Ala His Ile Val Met Val Asp Ala Tyr Lys Pro Thr225 230 235 240Lys Ala Met Ile Gly Ser Gln Glu Pro Val Ile Leu Ile Asp Lys Ile 245 250 255Glu Arg Cys Leu Val Val Glu Trp Tyr Glu Asn Asn Ile Arg Arg Glu 260 265 270Gln Arg Ile Ser Tyr Lys Lys Tyr Gly Asn Asp Lys Ala Lys Leu Arg 275 280 285Ala Lys Glu Leu Ile Glu Lys Leu Lys Ser Gly Ile Thr Phe Glu Gln 290 295 300Leu Tyr Pro Asp Lys Gly Pro Pro Ile Val Arg Val Phe Glu Asn Val305 310 315 320Gly Val Tyr Asn Val Ser Leu Ile Arg Asp Arg Ile Glu Arg Glu Trp 325 330 335Arg Val Glu Trp Leu Glu Asn Gly Val Pro Met Lys Ala Arg Trp Ser 340 345 350Cys Lys Lys Val Gly Asn Asp Glu Ala Gln Lys Arg Ala Asp Thr Phe 355 360 365Ala Gln Ser Met Ile Lys Gly Ile Phe Asn Pro 370 37524463PRTArtificial SequenceSpyTag-TTP BD 24Met Thr Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val1 5 10 15Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu 20 25 30His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe 35 40 45Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp 50 55 60Val Lys Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys65 70 75 80His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met 85 90 95Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala 100 105 110Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu 115 120 125Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr 130 135 140Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala145 150 155 160Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro 165 170 175Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp 180 185 190Lys Tyr Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp 195 200 205Gln Ala Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val 210 215 220Pro Arg Gly Ser Ser Met Gly Ser Ser His His His His His His Ser225 230 235 240Ser Gly Leu Val Pro Arg Gly Ser His Ile Ala His Ile Val Met Val 245 250 255Asp Ala Tyr Lys Pro Thr Lys His Met Asn Asn Asn Phe Asn Ile Asn 260 265 270Leu Gln Ile Glu Asp Gly Ile Thr Asn Lys Tyr Glu Ala Glu Val Asn 275 280 285Gly Tyr Phe Ala Lys Leu Tyr Thr Gly Glu Ile Thr Val Asn Thr Met 290 295 300Ile Asp Ile Met Lys Asn Leu Ser Cys Ser Pro Lys Gly Ser Lys Asn305 310 315 320Asn Asp Ile Tyr Lys Ser Met Leu Leu Ile Leu Phe Asn Glu Cys Lys 325 330 335Phe Phe Pro Lys Tyr Pro Val Glu Glu Leu Asp Ile Thr Ala Gln Leu 340 345 350Phe Gly Lys Leu Ile Lys His Asn Leu Leu Ile Ser Tyr Gly Asn Thr 355 360 365Leu Ser Val Val Leu Lys Cys Ile Leu Glu Ala Leu Lys Lys Gly Ser 370 375 380Asp Ser Lys Val Phe Asn Phe Gly Ile Thr Ala Leu Glu Gln Phe Glu385 390 395 400Asp Ser Leu Ile Cys Tyr Pro Ala Phe Leu Ser Ser Leu Ile Pro Leu 405 410 415Pro Thr Leu Arg Gln Tyr Asn Pro Gln Tyr Ile Ile His Cys Asn Glu 420 425 430Leu Leu Asn Thr Leu Pro Glu Gln Phe Arg Thr Leu Pro Tyr Ile Asp 435 440 445Ala Ser Thr Ile Leu Lys Ile Lys His Ile Ser Glu Ile Ser Ser 450 455 46025475PRTArtificial SequenceSpyTag-UIS12 RRM 1+2 25Met Thr Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val1 5 10 15Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu 20 25 30His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe 35 40 45Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp 50 55 60Val Lys Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys65 70 75 80His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met 85 90 95Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala 100 105 110Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu 115 120 125Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr 130 135 140Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala145 150 155 160Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro 165 170 175Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp 180 185 190Lys Tyr Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp 195 200 205Gln Ala Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val 210 215 220Pro Arg Gly Ser Ser Met Gly Ser Ser His His His His His His Ser225 230 235 240Ser Gly Leu Val Pro Arg Gly Ser His Ile Ala His Ile Val Met Val 245 250 255Asp Ala Tyr Lys Pro Thr Lys His Met Lys Asn Val Ile Ile Thr Asn 260 265 270Val Phe Leu Gly Asn Ile Pro Pro Asn Ile Thr Glu Glu Arg Leu Lys 275 280 285Asn Val Leu Glu Ile Phe Gly Tyr Ile Ile His Ile Glu Tyr Lys Trp 290 295 300Ser Leu Asp Lys Trp Ser Tyr Ala Phe Ile Tyr Phe Ile Glu Glu Lys305 310 315 320Cys Ala Ile Asn Ala Val Asn Ile Leu Asn Gln Lys Lys Phe Phe Asp 325 330 335Asn Ser Pro Asn His Lys Leu Ile Cys Phe Ile Val Ser Lys Gln Ile 340 345 350Pro Asn Gln Asn Thr Leu His Tyr Ser Lys Ala Asn Phe Ser Leu Leu 355 360 365Lys Asp Gly Pro Pro Gly Ala Asn Leu Phe Leu Tyr Gly Ile Pro Leu 370 375 380Lys Trp Thr Glu Leu Asn Leu Ile Gln Leu Val Asn Lys Tyr Gly His385 390 395 400Val Val Gly Leu Arg Ile Pro Tyr Ile Asn Asn Asp Asn Asp Lys Lys 405 410 415Gln Gly Asn Arg Gly Phe Gly Phe Val Ser Tyr Asp Asn Lys Lys Ser 420 425 430Ala Val Glu Ala Phe Glu Glu Leu Ser Lys Met Tyr Ile His Gly Lys 435 440 445Leu Leu Lys Val Gln Leu Lys Asn Gly Glu Glu Leu

Glu Asn Leu Tyr 450 455 460Phe Gln Gly Val Glu His His His His His His465 470 47526877PRTArtificial SequencePyPABP1-SpyTag 26Gly Ser Ser Met Gly Met Ile Ala Asn Ser Thr Asn Ile Met Pro Pro1 5 10 15Ser Phe Ser Thr Ala Ser Leu Tyr Val Gly Asp Leu Ser Glu Asp Val 20 25 30Thr Glu Ala Val Leu Tyr Glu Ile Phe Asn Thr Val Gly His Val Leu 35 40 45Ser Ile Arg Val Cys Arg Asp Ser Val Thr Arg Lys Ser Leu Gly Tyr 50 55 60Ala Tyr Val Asn Tyr His Asn Leu Ala Asp Ala Glu Arg Ala Leu Asp65 70 75 80Thr Leu Asn Tyr Thr Asn Ile Lys Gly Gln Pro Ala Arg Leu Met Trp 85 90 95Ser His Arg Asp Pro Ser Leu Arg Lys Ser Gly Thr Gly Asn Ile Phe 100 105 110Val Lys Asn Leu Asp Lys Thr Ile Asp Asn Lys Ala Leu Phe Asp Thr 115 120 125Phe Ser Met Phe Gly Asn Ile Leu Ser Cys Lys Val Ala Thr Asp Glu 130 135 140Phe Gly Lys Ser Lys Asn Tyr Gly Phe Val His Tyr Glu Asp Glu Glu145 150 155 160Ser Ala Lys Glu Ala Ile Glu Lys Val Asn Gly Met Gln Leu Gly Ser 165 170 175Lys Asn Val Tyr Val Gly His Phe Ile Lys Lys Ser Glu Arg Ala Thr 180 185 190Asn Asp Thr Lys Phe Thr Asn Leu Tyr Val Lys Asn Phe Pro Asp Thr 195 200 205Val Thr Glu Ala His Leu Lys Gln Leu Phe Ser Pro Tyr Gly Glu Ile 210 215 220Thr Ser Met Ile Val Lys Ser Asp Asn Lys Asn Arg Lys Phe Cys Phe225 230 235 240Ile Asn Tyr Ser Asp Ala Asp Ser Ala Arg Asn Ala Met Glu Asn Leu 245 250 255Asn Gly Lys Lys Ile Thr Glu Asp Gly Lys Ile Asp Tyr Asn Tyr Asp 260 265 270Pro Lys Lys Glu Glu Thr Glu Lys Pro Ala Asn Glu Asn Ser Asn Asn 275 280 285Asn Thr Thr Thr Glu Glu Asn Thr Thr Thr Ser Glu Thr Pro Ala Glu 290 295 300Lys Lys Thr Pro Asp Ser Glu Pro Ala Thr Asn Lys Asp Ala Thr Pro305 310 315 320Gly Glu Asp Gln Thr Ser Ala Asn Gly Thr Thr Thr Thr Val Thr Ser 325 330 335Thr Thr Asp Ala Asn Pro Asp Ser Lys Thr Glu Glu Thr Pro Asn Asp 340 345 350Asn Thr Ala Asn Ala Gly Thr Asn Ala Ser Thr Thr Glu Lys Lys Asp 355 360 365Asn Lys Lys Ser Gly Glu Asn Thr Glu Thr Pro Asn Ile Leu Tyr Val 370 375 380Gly Pro His Gln Ser Arg Ala Arg Arg His Ala Ile Leu Lys Ala Lys385 390 395 400Phe Asp Thr Leu Asn Thr Glu Ser Arg Asn Lys His Pro Gly Val Asn 405 410 415Leu Tyr Ile Lys Asn Leu Asp Asp Ser Met Asn Asp Gln Thr Leu Lys 420 425 430Glu Leu Phe Glu Pro Tyr Gly Thr Ile Thr Ser Ala Lys Val Met Lys 435 440 445Asp Asp Lys Asp Gln Ser Lys Gly Phe Gly Phe Val Cys Phe Gly Thr 450 455 460His Glu Glu Ala Asn Lys Ala Val Thr Glu Met His Leu Lys Ile Ile465 470 475 480Asn Gly Lys Pro Leu Tyr Val Gly Leu Ala Glu Lys Arg Glu Gln Arg 485 490 495Leu Ser Arg Leu Gln Gln Arg Phe Arg Met His Pro Ile Arg His His 500 505 510Ile Asn Asn Ala Leu Asn Ala Pro Ile Gln Tyr Pro Asn Ser Gln Thr 515 520 525Ala Gln Leu Gln Phe Asn Gln Asn Thr Leu Asn Tyr Gly Arg Pro Val 530 535 540Ile Thr Ser Phe Asn Gln Asn Asn Leu Ile Ser Trp Arg His Gln Gln545 550 555 560Ala Ala Ala Gln Gln Gln Ala Ala His Gln Gln Ala Ala Ala Gln Gln 565 570 575Gln Leu Gly Phe Asn Gly Gly Leu Arg Gly Gln Ile Asn Gln Met Arg 580 585 590Leu Tyr Thr Gln Asn Asn Met Ile Asn His Asn Ile Gly Gln Asn Lys 595 600 605Ala Asn Gln Gln Leu His His Asn Gln Gln Tyr Pro Ile Gly Pro Asn 610 615 620Pro Gln His Gln Gln Thr Asn Leu Asn Ala Pro Ala Gln Thr Asn Pro625 630 635 640Gln Gln Leu Gln Gly Ala Ala Pro Val Pro Thr Asn Gln Leu Leu Asn 645 650 655Asn Asn Met Arg Asn Met Asn Ser Arg Gly Asn Arg Asn Leu Pro Gly 660 665 670Ile Asn Ile Gln Ser Pro Lys Gln Met Pro Leu Asn Met Val Gly Ala 675 680 685Lys Gln Thr Asn Pro Gln Gln Asn Gln Pro Gln Asn Gln Pro Gln Asn 690 695 700Gln Pro Gln Gly Gln Pro Gln Asn Gln Pro Gln Gln Lys Ser Gly Gln705 710 715 720Ser Ile Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Thr Ile Pro Gln 725 730 735Asn Asn Asn Phe Lys Phe Thr Ser Gln Ala Arg Asn Arg Met Glu Leu 740 745 750Pro Asn Lys Asn Gly Asn Lys Val Asn Asn Met Thr Pro Gly Tyr Asn 755 760 765Asn Asn Thr Thr Leu Thr Ala Ala Ala Leu Ala Ser Ala Pro Pro Ser 770 775 780Met Gln Lys Gln Val Leu Gly Glu Asn Leu Phe Pro Leu Val Ala Asn785 790 795 800Tyr His Pro Thr Leu Ala Gly Lys Ile Thr Gly Met Met Leu Glu Met 805 810 815Asp Asn Ser Glu Leu Leu Ile Leu Leu Glu Asn Glu Asp Gln Leu Lys 820 825 830Lys Lys Ile Asp Glu Ala Leu Ala Val Leu Gln Asn Ala Lys Leu Glu 835 840 845Ala His Ile Val Met Val Asp Ala Tyr Lys Pro Thr Lys Val Glu Asn 850 855 860Leu Tyr Phe Gln Gly Val Glu His His His His His His865 870 87527155PRTArtificial SequenceSpyTag-2xAP2 27Gly Ser His Ser Ala His Ile Val Met Val Asp Ala Tyr Lys Pro Thr1 5 10 15Lys Ala Met Ile Gly Ser Gln Glu Pro Val Ile Leu Ile Asp Lys Ile 20 25 30Glu Arg Cys Leu Val Val Glu Trp Tyr Glu Asn Asn Ile Arg Arg Glu 35 40 45Gln Arg Ile Ser Tyr Lys Lys Tyr Gly Asn Asp Lys Ala Lys Leu Arg 50 55 60Ala Lys Glu Leu Ile Glu Lys Leu Lys Ser Gly Ile Thr Phe Glu Gln65 70 75 80Leu Tyr Pro Asp Lys Gly Pro Pro Ile Val Arg Val Phe Glu Asn Val 85 90 95Gly Val Tyr Asn Val Ser Leu Ile Arg Asp Arg Ile Glu Arg Glu Trp 100 105 110Arg Val Glu Trp Leu Glu Asn Gly Val Pro Met Lys Ala Arg Trp Ser 115 120 125Cys Lys Lys Val Gly Asn Asp Glu Ala Gln Lys Arg Ala Asp Thr Phe 130 135 140Ala Gln Ser Met Ile Lys Gly Ile Phe Asn Pro145 150 15528217PRTArtificial SequenceSpyTag-TTP BD 28Gly Ser His Ile Ala His Ile Val Met Val Asp Ala Tyr Lys Pro Thr1 5 10 15Lys His Met Asn Asn Asn Phe Asn Ile Asn Leu Gln Ile Glu Asp Gly 20 25 30Ile Thr Asn Lys Tyr Glu Ala Glu Val Asn Gly Tyr Phe Ala Lys Leu 35 40 45Tyr Thr Gly Glu Ile Thr Val Asn Thr Met Ile Asp Ile Met Lys Asn 50 55 60Leu Ser Cys Ser Pro Lys Gly Ser Lys Asn Asn Asp Ile Tyr Lys Ser65 70 75 80Met Leu Leu Ile Leu Phe Asn Glu Cys Lys Phe Phe Pro Lys Tyr Pro 85 90 95Val Glu Glu Leu Asp Ile Thr Ala Gln Leu Phe Gly Lys Leu Ile Lys 100 105 110His Asn Leu Leu Ile Ser Tyr Gly Asn Thr Leu Ser Val Val Leu Lys 115 120 125Cys Ile Leu Glu Ala Leu Lys Lys Gly Ser Asp Ser Lys Val Phe Asn 130 135 140Phe Gly Ile Thr Ala Leu Glu Gln Phe Glu Asp Ser Leu Ile Cys Tyr145 150 155 160Pro Ala Phe Leu Ser Ser Leu Ile Pro Leu Pro Thr Leu Arg Gln Tyr 165 170 175Asn Pro Gln Tyr Ile Ile His Cys Asn Glu Leu Leu Asn Thr Leu Pro 180 185 190Glu Gln Phe Arg Thr Leu Pro Tyr Ile Asp Ala Ser Thr Ile Leu Lys 195 200 205Ile Lys His Ile Ser Glu Ile Ser Ser 210 21529229PRTArtificial SequenceSpyTag-UIS12 29Gly Ser His Ile Ala His Ile Val Met Val Asp Ala Tyr Lys Pro Thr1 5 10 15Lys His Met Lys Asn Val Ile Ile Thr Asn Val Phe Leu Gly Asn Ile 20 25 30Pro Pro Asn Ile Thr Glu Glu Arg Leu Lys Asn Val Leu Glu Ile Phe 35 40 45Gly Tyr Ile Ile His Ile Glu Tyr Lys Trp Ser Leu Asp Lys Trp Ser 50 55 60Tyr Ala Phe Ile Tyr Phe Ile Glu Glu Lys Cys Ala Ile Asn Ala Val65 70 75 80Asn Ile Leu Asn Gln Lys Lys Phe Phe Asp Asn Ser Pro Asn His Lys 85 90 95Leu Ile Cys Phe Ile Val Ser Lys Gln Ile Pro Asn Gln Asn Thr Leu 100 105 110His Tyr Ser Lys Ala Asn Phe Ser Leu Leu Lys Asp Gly Pro Pro Gly 115 120 125Ala Asn Leu Phe Leu Tyr Gly Ile Pro Leu Lys Trp Thr Glu Leu Asn 130 135 140Leu Ile Gln Leu Val Asn Lys Tyr Gly His Val Val Gly Leu Arg Ile145 150 155 160Pro Tyr Ile Asn Asn Asp Asn Asp Lys Lys Gln Gly Asn Arg Gly Phe 165 170 175Gly Phe Val Ser Tyr Asp Asn Lys Lys Ser Ala Val Glu Ala Phe Glu 180 185 190Glu Leu Ser Lys Met Tyr Ile His Gly Lys Leu Leu Lys Val Gln Leu 195 200 205Lys Asn Gly Glu Glu Leu Glu Asn Leu Tyr Phe Gln Gly Val Glu His 210 215 220His His His His His225

Claims

1.-27. (canceled)

28. A process of immunizing a subject, comprising administering to the subject a three dimensional protein structure comprising: a multimeric self-assembling nanocage, the nanocage comprising a plurality of protein substructures, one or more of the protein substructures comprising a linker and a capture sequence on an N-terminus; and a target protein, the target protein comprising a tag, the tag complementary to the capture sequence to that an association between the tag and the capture sequence covalently bonds said target protein to said protein substructure, or non-covalently bonds said target protein to said protein substructure with a K.sub.D or 10.sup.12 M or lower.

29. The process of claim 28, wherein said linker is intermediate the protein substructure and the capture sequence, the linker covalently bonding the capture sequence to the protein substructure.

30. The process of claim 29, wherein the linker is a flexible linker.

31. The process of claim 30, wherein the flexible linker is selected from the group consisting of a multimer of the amino acid sequence GGS, GSS, or combinations thereof.

32. The process of claim 29, wherein the linker is a rigid linker.

33. The process of claim 32, wherein the rigid linker comprises one or more stabilizing disulfide bonds, one or more repeats of SEQ ID NO: 10, an amino acid sequence comprising 3 or more proline residues, an amino acid sequence comprising 1 or more sequences of PPA, or a combination thereof.

34. The process of claim 28, wherein each of said protein substructures comprises an amino acid sequence that is 70% or greater identical to any one of SEQ ID NOs:1-6.

35. The process of claim 28, wherein the capture sequence comprises the sequence of SEQ ID NO: 8, SEQ ID NO: 9, biotin, or avidin.

36. The process of claim 28, wherein the multimeric self-assembling protein structure comprises a multimer of any one of SEQ ID NOs: 1-6.

37. The process of claim 28, wherein the multimer is a 60-mer.

38. The process of claim 28, wherein the multimeric self-assembling protein structure forms a dodecahedron.

39. The process of claim 28, wherein the target protein has a molecular weight of less than 200 kDa.

40. The process of claim 28, wherein the target protein has a molecular weight of less than 150 kDa.

41. The process of claim 28, wherein the target protein has a molecular weight of less than 120 kDa.

42. The process of claim 28, wherein the tag comprises SEQ ID NO: 20, SEQ ID NO: 21, biotin, or avidin.

43. The process of claim 28, wherein said target protein is the RNA-binding protein, cytosolic Poly-A Binding Protein (PABP), a DNA-binding protein of the ApiAP2 specific transcription factor family, a binding domain of tristetraprolin (TTP) of a NOT family protein, or a RNA-recognition motif of the Upregulated in Infectious Sporozoites 12 (UIS12) protein.

44. The process of claim 28, wherein said target protein is saturated onto said multimeric self-assembling protein structure to form a target complex at a level of 50% or greater.

45. The process of claim 28, wherein said target protein is saturated onto said multimeric self-assembling protein structure to form a target complex at a level of 90% or greater.

46. The process of claim 28, wherein the protein structure is in an aqueous buffer comprising at or greater than 100 mM of a salt.

47. The process of claim 46, wherein the salt is 200 mM to 500 mM.